

FORM PTO-1390  
(Rev. 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

ATTORNEY'S DOCKET NUMBER  
640100-430

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)

**09/937974**

INTERNATIONAL APPLICATION NO.  
PCT/US00/08751

INTERNATIONAL FILING DATE  
31 March 2000

PRIORITY DATE CLAIMED  
1 April 1999

TITLE OF INVENTION

**HUMAN MESENCHYMAL DNAs AND EXPRESSION PRODUCTS**

APPLICANT(S) FOR DO/EO/US


**Christian Van den Bos and Gabriel Mbalaviele**

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to being national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is attached herewith (required only if not communicated by the International Bureau).
  - b. ☐ has been communicated by the International Bureau.
  - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**Items 11 to 20 below concern other document(s) or information included:**

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.
18. ☒ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 15(d)(4).
20. ☐ Other items or information:

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) <b>09/937974</b>		INTERNATIONAL APPLICATION NO. PCT/US00/08751		ATTORNEY'S DOCKET NUMBER 640100-430	
21. <input checked="" type="checkbox"/> The following fees are submitted: <b>Basic National Fee (37 CFR 1.492(a)(1)-(5)):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO and JPO ..... \$1000.00  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$860.00  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$710.00  International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$690.00  International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$100.00				<b>CALCULATIONS PTO USE ONLY</b>	
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				\$ 1,040.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 130.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	24 - 20 =	4	X \$18.00	\$ 72.00	
Independent Claims	6 - 3 =	3	X \$84.00	\$ 252.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$270.00				\$	
<b>TOTAL OF ABOVE CALCULATIONS</b>				\$ 1364.00	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2				\$ 682.00	
<b>SUBTOTAL</b>				\$ 682.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f))				\$	
<b>TOTAL NATIONAL FEE</b>				\$ 682.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$	
<b>TOTAL FEES ENCLOSED =</b>				\$ 682.00	
				Amount to be refunded: \$ charged: \$	
a. <input checked="" type="checkbox"/> A check no. _____ in the amount of \$682.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. <b>03-0678</b> in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <b>03-0678</b> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. Credit Card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>					
SEND ALL CORRESPONDENCE TO:					
Alan J. Grant, Esq. Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein 6 Becker Farm Roseland, New Jersey 07068				SIGNATURE  Alan J. Grant  NAME 33,389  REGISTRATION NUMBER	

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**  
**Patent Examining Operations**

Applicant(s): Van den Bos and Mbalaviele  
Serial No: PCT/US00/08751 Art Unit: Unassigned  
Filed: 31 March 2000 Examiner: Unassigned  
Title: HUMAN MESENCHYMAL DNAs AND EXPRESSION PRODUCTS  
Docket No: 640100-430

Commissioner for Patents  
Washington, D.C. 20231

**Preliminary Amendment**

Sir:

The above-referenced PCT application is filed herewith as a National-Stage application under 35 U.S.C. 371. Prior to examination on the merits, please enter the following amendment.

In the Specification:

Please amend the paragraph starting on page 1, line 8, to read as follows:

"This application is a national stage filing based on PCT/US00/08751 and claims the priority of U.S. Provisional Applications 60/148,800, filed 13 August 1999, and 60/127,418, filed 1 April 1999, the disclosures of which are hereby incorporated by reference in their entirety."

09/937974-011002

## REMARKS

The application filed herewith is a national stage filing under 35 U.S.C. 371 and the specification has been amended to reflect this.

The Commissioner is authorized to charge payment of any additional filing fees required under 37 CFR 1.16 associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

09937974-011002

<p><b>EXPRESS MAIL CERTIFICATE</b></p> <p>Express Mail Label No. EL680647645US</p> <p>Deposit Date: 1 October 2001</p> <p>I hereby certify that this paper and the attachments hereto are being deposited today with the U.S. Postal Service "Express Mail Post Office To Addressee" service under 37 CFR 1.10 on the date indicated above addressed to:</p> <p>Commissioner for Patents Washington, DC 20231</p> <p><i>Alan J. Grant</i> Alan J. Grant, Esq.</p> <p><i>10/1/01</i> Date</p>
--

Respectfully submitted,



Alan J. Grant, Esq.  
Reg. No. 33,389  
CARELLA, BYRNE, BAIN, GILFILLAN,  
CECCHI, STEWART & OLSTEIN  
6 Becker Farm Road  
Roseland, NJ 07068  
Tel. No.: (973) 994-1700

## AMENDED SPECIFICATION

The paragraph starting on page 1, line 8, has been amended as follows:

"This application is a national stage filing based on PCT/US00/08751 and claims the priority of U.S. Provisional Applications 60/148,800, filed 13 August 1999, and 60/127,418, filed 1 April 1999, the disclosures of which are hereby incorporated by reference in their entirety."

## HUMAN MESENCHYMAL DNAs AND EXPRESSION PRODUCTS

5

This application claims the priority of U.S. Provisional Applications 60/148,800, filed 13 August 1999, and 60/127,418, filed 1 April 1999, the disclosures of which are hereby incorporated by reference in their entirety.

15

### BACKGROUND OF THE INVENTION

This invention relates to newly identified polynucleotide sequences corresponding to transcription products of human genes, and to complete gene sequences associated therewith and to gene expression products thereof and to uses for the foregoing.

Osteoblasts, key cells in bone formation, or osteogenesis, are formed from mesenchymal stem cells. Such mesenchymal stem cells (or MSCs) of numerous mammalian species can be induced to differentiate into connective tissue cell lineages by varying the *in vitro* culture conditions. Osteogenesis, the differentiation into bone cells, has been reported as a means to generate replacement bone from cultured and implanted MSCs (Bruder et al, Growth Kinetics, Self-Renewal, and the Osteogenic Potential of Purified Human Mesenchymal Stem Cells During Extensive Subcultivation and Following Cryopreservation, J. Cell Biochem., 64(2):278-294 (Feb. 1997); Jaiswal et al., Osteogenic Differentiation of Purified, Culture-Expanded Human Mesenchymal Stem

Cells In Vitro, J. Cell Biochem., 64(2):295-312 (Feb. 1997), Kadiyala et al., Culture Expanded Canine Mesenchymal Stem Cells Possess Osteochondrogenic Potential In Vivo and In Vitro, Cell Transplant, 6(2):125-134 (Mar-Apr 1997)).

5

The process by which MSCs undergo osteogenic differentiation in culture is marked by the development of an osteoblastic morphology, the deposition of a hydroxyapatite mineralized extracellular matrix characteristic of osteoblasts and the presence of terminally differentiated osteocytes, as well as the expression of alkaline phosphatase (Jaiswal et al., Osteogenic Differentiation of Purified, Culture-Expanded Human Mesenchymal Stem Cells In Vitro, J. Cell Biochem., 64(2):295-312 (Feb. 1997)). Mechanisms underlying the osteogenic differentiation of human MSCs (hereafter, hMSCs) are poorly understood. Identification of proteins produced during this process would greatly facilitate the discovery and development of small molecules that target the osteoblast and its bone forming potential. Identification of these factors would be accelerated by the availability of relevant cDNA libraries constructed from hMSCs during various stages of their differentiation.

Identification and sequencing of human genes is a major goal of modern Molecular Biology. For example, by identifying genes and determining their sequences, scientists have been able to make large quantities of valuable human "gene products." These include human insulin, interferon, Factor VIII, tumor necrosis factor, human growth hormone, tissue plasminogen activator, and numerous other compounds. Additionally, knowledge of gene sequences can provide the key to treatment or cure of genetic diseases (such as muscular dystrophy and cystic fibrosis).

**BRIEF SUMMARY OF THE INVENTION**

5

In accordance with the present invention, Mesenchymal stem cells (MSCs) have been isolated and culture expanded from humans, and from them new cDNA libraries have been constructed from messenger ribonucleic acids (hereafter, mRNAs) isolated from hMSCs.

10

It is an object of the present invention to obtain cDNA libraries from purified and cultured MSCs and to use these isolated nucleic acids, isolated sequences, and fragments thereof, in the determination and preparation of the expression products of these nucleic acids and sequences, including fragments thereof.

15

It is a further object of the present invention to use the cDNAs so produced, and fragments thereof, as well as their expression products, as chromosomal markers for determining the location of genes within the genome, and alleles thereof, expressed during the development of differentiated mesenchymal cells.

20

It is yet another object of the present invention to provide DNA sequences for use in human "fingerprinting" whereby different individuals can be distinguished based on the sequences of the genes identified as wholly, or partly, identical to those disclosed herein.

25

It is still another object of the present invention to provide polynucleotide sequences corresponding to the genes coding for polypeptides as disclosed herein whereby such sequences can be compared with those found in similar chromosomal locations in animals, especially mammals, and most especially humans, where such animal is

30

afflicted with a disease affecting bone growth, or such other disease, or diseases, as may be affected by such genes, and thus detecting the presence of mutations in said genes leading to such diseases.

5 It is a still further object of the present invention to provide genetically engineered cells, and vectors, containing one or more copies of the nucleic acids, or DNAs, or genes, or nucleotide sequences according to the present invention, capable of expressing said peptides, or polypeptides, or proteins for rapid cloning of genes according to the  
10 present invention.

#### BRIEF DESCRIPTION OF THE DRAWINGS

15 Figure 1 shows the consensus sequence (SEQ ID NO: 27) for the novel DNA sequence of the invention as determined from different cDNA clones of said sequence, the latter being about 2.5 kb in length.

20 Figure 2 is a deduced amino acid sequence for the protein expressed from the sequence of Figure 1, residues 125 through 1717 and corresponding to SEQ ID NO:29. The amino acids set off between asterisks constitute a bipartite nuclear localization signal. The isoelectric point and molecular weight were also calculated for the putative protein.

25 Figure 3 shows the results of a dot blot assay for the presence of the novel DNA sequence in a variety of human tissues. For this assay, a prefabricated dot blot from Clontech (#7770-1) was hybridized using a probe generated from the 2.5 kb cDNA of Figure 1 and  
30 treated according to the manufacturer's instructions. Signals due to bound probe were analyzed using a Storm 860 phosphorimager and imagequant software.

Figure 4 is a bar graph showing the distribution of the sequence of Figure 1 in a variety of human tissues based on relative mRNA abundance. The highest signal strength was in cells of adult heart and lowest was in fetal thymus. The bar graphs were generated using data from the dot blots of Figure 3 and were imported into an Excel spreadsheet. The data were then analyzed as arbitrary signal strength per tissue after subtracting background (due to non-specific hybridization). The order of the tissues in the bar graph reflects signal strength (and therefore differs from that on the dot blot of Figure 3). Figure 4(b) is a continuation of Figure 4(a).

15

#### DETAILED DESCRIPTION OF THE INVENTION

One aspect of the present invention is directed to nucleic acids and isolated DNA sequences and molecules, and fragments thereof (and corresponding isolated RNA sequences, and fragments thereof), including sequences complementary to the foregoing, showing sequence similarity to, or capable of hybridizing to, the DNA sequences identified in SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27 or 28. The present invention is also directed to fragments or portions of such sequences which contain at least 15 bases, preferably at least 30 bases, more preferably at least 50 bases and most preferably at least 80 bases, and to those sequences which are at least 60%, preferably at least 80%, and most preferably at least 95%, especially 98%, identical thereto, and to DNA (or RNA) sequences encoding the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 29, including fragments and portions thereof and, when derived from natural sources, includes alleles thereof.

In accordance with the present invention, the term "percent identity" or "percent identical," when referring to a sequence, means that a sequence is compared to a claimed or described sequence after alignment of the sequence to be compared (the "Compared Sequence") with the described or claimed sequence (the "Reference Sequence"). The Percent Identity is then determined according to the following formula:

$$\text{Percent Identity} = 100 [1 - (C/R)]$$

10

wherein C is the number of differences between the Reference Sequence and the Compared Sequence over the length of alignment between the Reference Sequence and the Compared Sequence wherein (i) each base or amino acid in the Reference Sequence that does not have a corresponding aligned base or amino acid in the Compared Sequence and (ii) each gap in the Reference Sequence and (iii) each aligned base or amino acid in the Reference Sequence that is different from an aligned base or amino acid in the Compared Sequence, constitutes a difference; and R is the number of bases or amino acids in the Reference Sequence over the length of the alignment with the Compared Sequence with any gap created in the Reference Sequence also being counted as a base or amino acid.

If an alignment exists between the Compared Sequence and the Reference Sequence in which the percent identity as calculated above is about equal to or greater than a specified minimum Percent Identity then the Compared Sequence has the specified minimum percent identity to the Reference Sequence even though alignments may exist in which the hereinabove calculated Percent Identity is less than the specified Percent Identity.

30

Yet another aspect of the present invention is directed to an isolated DNA (or RNA) sequence or molecule comprising at least the

coding region of a human gene (or a DNA sequence encoding the same polypeptide as such coding region), in particular an expressed human gene, which human gene comprises a DNA sequence homologous with, or contributing to, the sequence depicted in SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and 27 or 28, or one at least 60%, preferably at least 80%, and most preferably at least 95%, especially 98%, identical thereto, including 100% identity, as well as fragments or portions of the coding region which encode a polypeptide having a similar function to the polypeptide encoded by said coding region. Thus, the isolated DNA (or RNA) sequence may include only the coding region of the expressed gene (or fragment or portion thereof as hereinabove indicated) or may further include all or a portion of the non-coding DNA (or RNA) of the expressed human gene.

In general, sequences homologous with and contributing to the sequences of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and 27 or 28 (or one at least 60%, preferably at least 80%, and most preferably at least 95% identical or homologous thereto) are from the coding region of a human gene.

The present invention also relates to vectors or plasmids which include such DNA (or RNA) sequences, as well as the use of the DNA (or RNA) sequences.

The sequences depicted in SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and 28 are hybridizable with actual DNA and RNA sequences as derived from different human tissues. These sequences represent cDNA clones.

The sequence depicted in Figure 1 (SEQ ID NO: 27) is hybridizable with actual DNA and RNA sequences as derived from different human tissues. A number of cDNA clones have been generated. The nucleotide

sequence of Figure 1 (SEQ ID NO: 27) itself showed a nuclear location in the various tissues studied. The distribution of this sequence in various human tissues is shown in Figures 3 and 4. Some of these clones had an additional 3'-untranslated region, the presence of which is generally related to the extent to which the mRNA species remain in the cell before being turned over. See Kingman, Genetic Engineering, Blackwell, 1988, at page 313. The 3'-untranslated region may also regulate the frequency at which the mRNA is translated and thus constitute a mechanism by which the expression of the protein can be regulated. (Gray, N.K. & Wickens, M., Control of Translation Initiation in Animals, Ann. Rev. Cell Dev. Biol., 14:399-458 (1998).

The polynucleotides of the present invention may be in the form of RNA or in the form of DNA, which DNA includes cDNA, genomic DNA, and synthetic DNA. The DNA may be double-stranded or single-stranded, and if single stranded may be the coding strand or non-coding (anti-sense) strand. The coding sequence which encodes the mature polypeptide may be identical to the coding sequences present as open reading frames (ORFs) of the spolynucleotide sequences disclosed herein or may be a different coding sequence, which coding sequence, as a result of the redundancy or degeneracy of the genetic code, encodes the same mature polypeptide as the polynucleotide sequences of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and 28.

The polynucleotides that code for the polypeptides disclosed herein as putative proteins SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 29 may include, but are not limited to: only the coding sequence for the mature polypeptide; the coding sequence for the mature polypeptide and additional coding sequence such as a leader or secretory sequence, a proprotein sequence and a membrane anchor; the coding sequence for the mature polypeptide (and optionally additional coding sequence) and non-coding sequence, such as introns or non-coding

sequence 5' and/or 3' of the coding sequence for the mature polypeptide.

The polynucleotide which codes for the polypeptide of Figure 2 (SEQ ID NO:29) may include, but is not limited to: only the coding  
5 sequence for the mature polypeptide; the coding sequence for the mature polypeptide and additional coding sequence such as a leader or secretory sequence, a proprotein sequence and a membrane anchor; the coding sequence for the mature polypeptide (and optionally additional coding sequence) and non-coding sequence, such as introns or non-coding  
10 sequence 5' and/or 3' of the coding sequence for the mature polypeptide.

The term "polynucleotide" as used for the present invention encompasses a polynucleotide which includes only coding sequence for the  
15 polypeptide as well as a polynucleotide which includes additional coding and/or non-coding sequences.

The present invention further relates to variants of the hereinabove described polynucleotides which encode fragments, analogs  
20 and derivatives of the polypeptides having the amino acid sequences of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 29. Variants of the polynucleotide may be naturally occurring allelic variants of the polynucleotides or a non-naturally occurring variant of the polynucleotides.

25

Thus, the nucleic acids, or polynucleotides, according to the present invention may have coding sequences which are naturally occurring allelic variants of the coding sequence shown in SEQ ID NOS: 1, 3, 5, 7, 9,  
11, 13, 15, 17, 19, 21, 23, 25, 27 and 28. As known in the art, an  
30 allelic variant is an alternate form of a polynucleotide sequence which may have a substitution, deletion or addition of one or more nucleotides, which does not substantially alter the function of the encoded polypeptide.

The present invention also includes polynucleotides, wherein the coding sequence for the mature polypeptide may be fused in the same reading frame to a polynucleotide sequence which aids in expression and secretion of a polypeptide from a host cell, for example, a leader sequence which functions as a secretory sequence for controlling transport of a polypeptide from the cell and a transmembrane anchor which facilitates attachment of the polypeptide to a cellular membrane. The polypeptide having a leader sequence is a preprotein and may have the leader sequence cleaved by the host cell to form the mature polypeptide. The polynucleotides may also encode for a proprotein which is the mature protein plus additional 5' amino acid residues. A mature protein having a prosequence is a proprotein and is often an inactive form of the protein. Once the prosequence is cleaved an active mature protein remains.

Thus, for example, the polynucleotide of the present invention may encode for a mature protein, for a protein having a prosequence, for a protein having a transmembrane anchor or for a polypeptide having a prosequence, a presequence (leader sequence) and a transmembrane anchor.

The polynucleotides of the present invention may also have the coding sequence fused in frame to a marker sequence which allows for purification of the polypeptide of the present invention. The marker sequence may be a hexa-histidine tag supplied by a pQE-9 vector to provide for purification of the mature polypeptide fused to the marker in the case of a bacterial host, or, for example, the marker sequence may be a hemagglutinin (HA) tag when a mammalian host, e.g. COS-7 cells, is used. The HA tag corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson, I., et al., Cell, 37:767 (1984)).

Fragments of the full length polynucleotide of the present invention may be used as hybridization probes for a cDNA library to isolate

the full length cDNA and to isolate other cDNAs which have a high sequence similarity to the gene or similar biological activity. Probes of this type preferably have at least 15 bases, may have at least 30 bases and even 50 or more bases. The probe may also be used to identify a cDNA clone corresponding to a full length transcript and a genomic clone or clones that contain the complete gene including regulatory and promotor regions, exons, and introns. An example of a screen comprises isolating the coding region of the gene by using the known DNA sequence to synthesize an oligonucleotide probe. Labeled oligonucleotides having a sequence complementary to that of the gene of the present invention are used to screen a library of human cDNA, genomic DNA or mRNA to determine which members of the library the probe hybridizes to.

A polynucleotide according to the present invention may have at least 15 bases, preferably at least 30 bases, and more preferably at least 50 bases which hybridize to a polynucleotide of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 28 and which has an identity thereto, as hereinabove described, and which may or may not retain activity. Such polynucleotides may be employed as probes for the polynucleotides or genes coding for the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 29, for example, for recovery of the polynucleotide or as a diagnostic probe or as a PCR primer.

The polynucleotides according to the present invention may also occur in the form of mixtures of polynucleotides hybridizable to some extent with the gene sequences containing any of the nucleotide sequences of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 28 including any and all fragments thereof, and which polynucleotide mixtures may be composed of any number of such polynucleotides, or fragments thereof, including mixtures having at least 10, perhaps at least 30 such sequences, or fragments thereof.

Because coding regions comprise only a small portion of the human genome, identification and mapping of transcribed regions and coding regions of chromosomes is of significant interest. There is a corresponding need for reagents for identifying and marking coding regions and transcribed regions of chromosomes. Furthermore, such human sequences are valuable for chromosome mapping, human identification, identification of tissue type and origin, forensic identification, and locating disease-associated genes (i.e., genes that are associated with an inherited human disease, whether through mutation, deletion, or faulty gene expression) on the chromosome.

Various aspects of the present invention include each of the individual sequences, corresponding partial and complete cDNAs, genomic DNA, mRNA, antisense strands, PCR primers, coding regions, and constructs. Expression vectors and polypeptide expression products, are also within the scope of the present invention, along with antibodies, especially monoclonal antibodies, to such expression products.

As used herein and except as noted otherwise, all terms are defined as given below.

In accordance with the present invention, the term "gene" or "cistron" means the segment of DNA (or DNA segment) involved in producing a polypeptide chain; it includes regions preceding and following the coding region (5'- and 3'- untranslated regions, or UTRs, also called leader and trailer sequences, regions, or segments) as well as intervening sequences (introns) between individual coding segments (exons), which intronic regions are typically removed during processing of post-transcriptional RNA to form the final translatable mRNA product. Of course, by their nature, cDNAs contain no intronic sequences.

In accordance with the present invention, the term "DNA segment" refers to a DNA polymer, in the form of a separate fragment or as a component of a larger DNA construct, which has been derived from DNA isolated at least once in substantially pure form, i.e., free of  
5 contaminating endogenous materials and in a quantity or concentration enabling identification, manipulation, and recovery of the segment and its component nucleotide sequences by standard biochemical methods, for example, using a cloning vector. Such segments are provided in the form of an open reading frame uninterrupted by internal nontranslated  
10 sequences (introns), which are typically present in eukaryotic genes. Sequences of non-translated DNA may be present downstream from the open reading frame, where the same do not interfere with manipulation or expression of the coding regions.

The nucleic acids and polypeptide expression products disclosed according to the present invention, as well as expression vectors containing such nucleic acids, may be in "enriched form." As used herein, the term "enriched" means that the concentration of the material is at least about 2, 5, 10, 100, or 1000 times its natural  
20 concentration (for example), advantageously 0.01%, by weight, preferably at least about 0.1% by weight. Enriched preparations of about 0.5%, 1%, 5%, 10%, and 20% by weight are also contemplated. The sequences, constructs, vectors, clones, and other materials comprising the present invention can advantageously be in enriched or isolated form.  
25 For example, removal, via the differential display techniques described herein, of clones corresponding to ribosomal RNA and "housekeeping" genes and clones without human cDNA inserts results in a library that is "enriched" in the desired clones.

The DNA and RNA sequences, and polypeptides, disclosed in accordance with the present invention will commonly be in isolated form. The term "isolated" means that the material is removed from its original

environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide, or DNA, present in a living animal is not isolated, but the same polynucleotide or DNA, separated from some or all of the coexisting materials in the natural system, is isolated. Such DNA could be part of a vector and/or such polynucleotide could be part of a composition, and still be isolated in that such vector or polynucleotide is not part of its natural environment.

The DNA and RNA sequences, and polypeptides, disclosed in accordance with the present invention may also be in "purified" form. The term "purified" does not require absolute purity; rather, it is intended as a relative definition, and can include preparations that are highly purified or preparations that are only partially purified, as those terms are understood by those of skill in the relevant art. Individual clones isolated from a cDNA library have been conventionally purified to electrophoretic homogeneity. The cDNA clones are obtained via manipulation of a partially purified naturally occurring substance (messenger RNA). By conversion of mRNA into a cDNA library, pure individual cDNA clones can be isolated from the synthetic library by clonal selection. Thus, creating a cDNA library from RNA and subsequently isolating individual clones from that library results in an approximately  $10^6$  fold purification of the native message. Purification of starting material or natural material to at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated. Furthermore, claimed polynucleotide which has a purity of preferably 0.001%, or at least 0.01% or 0.1%; and even desirably 1% by weight or greater is expressly contemplated.

The term "coding region" refers to that portion of a human gene which either naturally or normally codes for the expression product of that gene in its natural genomic environment, i.e., the region coding *in vivo* for the native expression product of the gene. The coding region can

be from a normal, mutated or altered gene, or can even be from a DNA sequence, or gene, wholly synthesized in the laboratory using methods well known to those of skill in the art of DNA synthesis.

5 In accordance with the present invention, the term "nucleotide sequence" refers to a heteropolymer of deoxyribonucleotides. Generally, DNA segments encoding the proteins provided by this invention are assembled from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene which is  
10 capable of being expressed in a recombinant transcriptional unit comprising regulatory elements derived from a microbial or viral operon.

The term "expression product" means that polypeptide or protein that is the natural transcription product of the gene and any  
15 nucleic acid sequence coding equivalents resulting from genetic code degeneracy and thus coding for the same amino acid(s).

The term "fragment" when referring to a coding sequence means a portion of DNA comprising less than the complete human coding  
20 region whose expression product retains essentially the same biological function or activity as the expression product of the complete coding region.

When referring to a portion of a polypeptide, as used herein,  
25 the terms "portion," "segment," and "fragment," refer to a continuous sequence of residues, such as amino acid residues, which sequence forms a subset of a larger sequence. For example, if a polypeptide were subjected to treatment with any of the common endopeptidases, such as trypsin or chymotrypsin, the oligopeptides resulting from such treatment would  
30 represent portions, segments or fragments of the starting polypeptide. Similarly, portions, segments or fragments of polynucleotides would include those products resulting from the treatment of such polynucleotides with

endonucleases.

The term "primer" means a short nucleic acid sequence that is paired with one strand of DNA and provides a free 3'OH end at which a  
5 DNA polymerase starts synthesis of a deoxyribonucleotide chain.

The term "promoter" means a region of DNA involved in binding of RNA polymerase to initiate transcription.

10 The term "open reading frame (ORF)" means a series of triplets coding for amino acids without any termination codons and is a sequence (potentially) translatable into protein.

The term "exon" means any segment of an interrupted gene  
15 that is represented in the mature RNA product.

As used herein, reference to a DNA sequence includes both single stranded and double stranded DNA. Thus, the specific sequence, unless the context indicates otherwise, refers to the single strand DNA of  
20 such sequence, the duplex of such sequence with its complement (double stranded DNA) and the complement of such sequence.

In accordance with the present invention, the overall approach to identification of cDNAs from hMSCs involved measurement  
25 of gene expression during growth of human mesenchymal stem cells in culture. Cells were harvested and the total RNA content thereof was recovered. Next, using various primer combinations, reverse transcriptase and polymerase chain reaction procedures (RT-PCR) were used to produce and amplify the corresponding cDNAs, which were then screened to find  
30 regulated DNA sequences that were subsequently purified and cloned. These clones were then sequenced and used to determine a consensus sequence (one based upon the most commonly occurring bases at each

nucleotide position in a sequence after the contributing sequences are aligned by residue position). The resulting sequences were then subjected to computer database searches for novelty, and any homology with known sequences, using, for example, the BLAST program and the GenBank database.

Using the RT-PCR methodology, the mRNA from the cells of interest (such as the hMSCs used in accordance with the present invention) is used to prepare a set or family of cDNAs corresponding to the expressed genes of the cell. This cDNA preparation is then exhaustively hybridized with mRNA of cells not expressing the gene and resulting in removal of all sequences from the cDNA preparation that are common to the two cell samples. All of the cDNA sequences that hybridize with the other mRNA and those that remain are then hybridized with mRNA from the cells expressing the gene (for example, cells from a healthy person or cells from tissues known to express the gene) to confirm that they are in fact the desired coding sequences. Because these latter clones contain sequences specific to the mRNA population of the cells of interest, they can subsequently be amplified and characterized using further rounds of PCR and the general techniques of molecular biology.

In accordance with the foregoing, a cDNA library was generated and corresponds to the sequences of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 28. Probes based on these cDNAs can be used to identify the relevant transcripts, using Northern Blotting Analysis methods well known in the art to localize these sequences within cells of various tissues. For example, the heaviest distribution of the gene coding for the polypeptide of Figure 2 (SEQ ID NO: 29) was in heart tissue, as shown in Figures 3 and 4.

In accordance with the present invention, cDNA was quantified by spotting 0.5  $\mu$ l aliquots of standards and samples on ethidium agarose plates prepared as suggested in the instructions from the manufacturer (Stratagene, La Jolla, CA). Plates were incubated at room temperature for 15 minutes and DNA was visualized by UV transillumination. The respective cDNAs were then quantified by comparing spot intensities of the samples with those of the standards (the latter consisting of appropriate dilutions of 1 kb ladders (from Life Technology)).

Aliquots of each amplified library were excised and plasmids from randomly chosen colonies were analyzed by restriction nuclease analysis. In accordance with the present invention, plasmid DNA was digested with both EcoRI and XhoI nucleases (New England Biolabs) and the resulting restriction fragments were separated on 1.5% agarose gel electrophoresis. The cDNA inserts ranged in size from less than 1 kbp to larger than 4 kbp (where 1 kbp = 1,000 nucleotide base pairs of duplex DNA).

Each of the DNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. The sequences can be used as diagnostic probes for the presence of a specific mRNA in a particular cell type as well as in genetic linkage analysis (polymorphisms). Further, the sequences can be used as probes for locating gene regions associated with genetic disease.

The nucleotide and gene sequences of the present invention are also valuable for chromosome identification. Each sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. Moreover, there is a current need for identifying particular sites on the chromosome. The mapping of the

polynucleotides to specific chromosomes according to the present invention is an important first step in correlating those sequences with genes associated with disease.

5 Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-30 bp) from the sequences disclosed herein. Computer analysis of these sequences is used to rapidly select primers that do not span more than one exon in the corresponding genomic DNA, which would otherwise complicate the amplification  
10 process. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the sequences or subsequences disclosed herein will yield an amplified fragment.

15 PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more clones can be assigned per day using a single thermal cycler, as is well known in the art. Using the present invention with the same oligonucleotide primers, sublocalization can be achieved with panels of  
20 fragments from specific chromosomes or pools of large genomic clones in an analogous manner. Other mapping strategies that can similarly be used to map a sequence, or part of a sequence, to its chromosome include *in situ* hybridization, prescreening with labeled flow-sorted chromosomes and preselection by hybridization to construct chromosome  
25 specific-cDNA libraries.

Fluorescence *in situ* hybridization (FISH) of a cDNA clone to a metaphase chromosomal spread can be used to provide a precise chromosomal location in one step. This technique can be used with  
30 cDNA as short as 500 or 600 bases; however, clones larger than 2,000 bp have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. FISH requires use of

the clone from which the sequence was derived, and the longer the better. For example, 2,000 bp is good, 4,000 is better, but more than 4,000 is probably not necessary to get good results a reasonable percentage of the time. For a review of this technique, see Verma et al.,  
5 Human Chromosomes: a Manual of Basic Techniques. Pergamon Press, New York (1988).

Reagents for chromosome mapping can be used individually (to mark a single chromosome or a single site on that chromosome) or as  
10 panels of reagents (for marking multiple sites and/or multiple chromosomes). Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. (Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man  
20 (available on line through Johns Hopkins University Welch Medical Library)). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically close genes).

Next, it is necessary to determine if there are differences in the cDNA or genomic sequence between affected and unaffected individuals. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.

With current resolution of physical mapping and genetic mapping techniques, a cDNA precisely localized to a chromosomal region

associated with the disease could be one of between 50 and 500 potential causative genes. (This assumes 1 megabase mapping resolution and one gene per 20 kb.)

5                   Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that cDNA sequence. Ultimately, complete sequencing of genes from several individuals is required to  
10 confirm the presence of a mutation and to distinguish mutations from polymorphisms.

                  In addition to the foregoing, the sequences of the invention, as broadly described, can be used to control gene expression through  
15 triple helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide sequence to DNA or RNA. Polynucleotides suitable for use in these methods are usually 20 to 40 bases in length and are designed to be complementary to a region of the gene involved in transcription (triple helix - see Lee et al, Nucl. Acids Res.,  
20 6:3073 (1979); Cooney et al, Science, 241:456 (1988) ; and Dervan et al, Science, 251: 1360 (1991) ) or to the mRNA itself (antisense - Okano, J. Neurochem., 56:560 (1991) ; Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)). Triple  
25 helix- formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques have been demonstrated to be effective in model systems. Information contained in the sequences of the present invention is necessary for the design of an antisense or triple  
30 helix oligonucleotide. Antisense RNA or oligonucleotide hybridization may also lead to RNase H activation and hence destruction of the molecules involved in the hybrid.

The present invention is also a useful tool in gene therapy, which requires isolation of the disease-associated gene in question as a prerequisite to the insertion of a normal gene into an organism to correct a genetic defect. The high specificity of the cDNA probes according to  
5 this invention have promise of targeting such gene locations in a highly accurate manner.

The sequences of the present invention, as broadly defined, and including subsequences and fragments thereof, are also useful for  
10 identification of individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands  
15 for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The sequences of the present invention are useful as additional DNA markers for RFLP.

However, RFLP is a pattern based technique, which does not  
20 require the DNA sequence of the individual to be sequenced. Portions of the sequences of the present invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual's genome. These  
25 sequences can also be used to prepare PCR primers for amplifying and isolating such selected DNA. One can, for example, take part of the sequence of the invention and prepare two PCR primers from the 5' and 3' ends of the sequence, or fragment of the sequence. These are used to amplify an individual's DNA, corresponding to the sequence. The  
30 amplified DNA is sequenced.

If a panel of reagents from the sequences according to the present invention is used to generate a unique ID database for an individual, those same reagents can later be used to identify tissue from that individual. Positive identification of that individual, living or dead can be made from extremely small tissue samples.

Another use for DNA-based identification techniques is in forensic biology. PCR technology can be used to amplify DNA sequences taken from very small biological samples. In one prior art technique, gene sequences are amplified at specific loci known to contain a large number of allelic variations, for example the DQ $\alpha$  class II HLA gene (Erich, H., PCR Technology, Freeman and Co. (1992)). Once this specific area of the genome is amplified, it is digested with one or more restriction enzymes to yield an identifying set of bands on a Southern blot probed with DNA corresponding to the DQ $\alpha$  class II HLA gene. In accordance with the present invention, it is clear from the results depicted in Figure 3

and 4 that the novel gene signal according to the present invention is found in many different tissues of the body.

5 The sequences of the present invention can be used to provide polynucleotide reagents specifically targeted to additional loci in the human genome, and can enhance the reliability of DNA-based forensic identifications. Those sequences targeted to noncoding regions are particularly appropriate. As mentioned above, actual base sequence information can be used for identification as an accurate alternative to  
10 patterns formed by restriction enzyme generated fragments. Reagents for obtaining such sequence information are within the scope of the present invention. Such reagents can comprise complete genes, parts of genes or corresponding coding regions, or fragments of at least 15 bp, preferably at least 18 bp.

15

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue  
20 prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar manner, these reagents can be used to screen tissue cultures for contamination.

25

Sequences that match perfectly to several different genes can be detected by hybridizing to chromosomes: if many chromosomal loci are observed, the sequence (or a close variant) is in more than one gene. This problem can be circumvented by using the 3'-untranslated part of the cDNA alone as a probe for the chromosomal location or for the  
30 full-length cDNA or gene. The 3'-untranslated region is more likely to be unique within gene families, since there is no evolutionary pressure to conserve a coding function of this region of the mRNA.

The cDNA libraries disclosed according to the present invention ideally use directional cloning methods so that either the 5' end of the cDNA (likely to contain coding sequence) or the 3' end (likely to be a non-coding sequence) can be selectively obtained.

Using the sequence information provided herein, the polynucleotides of the present invention can be derived from natural sources or synthesized using known methods. The sequences falling within the scope of the present invention are not limited to the specific sequences described, but include human allelic and species variations thereof. Allelic variations can be routinely determined by comparison of one sequence with a sequence from another individual of the same species. Furthermore, to accommodate codon variability, the inventor includes sequences coding for the same amino acid sequences as do the specific sequences disclosed herein. In other words, in a coding region, substitution of one codon for another which encodes the same amino acid is expressly contemplated. (Coding regions can be determined through routine sequence analysis.)

In a cDNA library there are many species of mRNA represented. Each cDNA clone can be interesting in its own right, but must be isolated from the library before further experimentation can be completed. In order to sequence any specific cDNA, it must be removed and separated (i.e. isolated and purified) from all the other sequences. This can be accomplished by many techniques known to those of skill in the art. These procedures normally involve identification of a bacterial colony containing the cDNA of interest and further amplification of that bacteria. Once a cDNA is separated from the mixed clone library, it can be used as a template for further procedures such as nucleotide sequencing.

The present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above. The constructs comprise a vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises regulatory sequences, including for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example. Bacterial: pBs, phagescript, PsiX174, pBluescript SK, pBs KS, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene); pTrc99A, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia). Eukaryotic: pWLeuo, pSV2cat, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia).

Thus, the present invention is not restricted to such constructs or sequences alone but also includes expression vehicles, which may include plasmids, viruses, or any other expression vectors, including cells and liposomes, containing any of the nucleic acids, nucleotide sequences, DNAs, RNAs, or fragments thereof, as disclosed according to the present invention. Furthermore, this will be true regardless of whether such sequences are coding sequences or non-coding sequences and whether such coding sequences code for all or part of the expression products as disclosed herein, so long as such expression products, or fragments thereof, exhibit some utility in keeping with the invention disclosed herein. Thus, while the present invention includes an isolated DNA sequence, or nucleic acid, that expresses a human protein when in a suitable expression system, for example, a cell-free, or *in vitro*, expression system, such system may also be contained in, or part of, a suitable expression vehicle, or vector, be that a cell, a plasmid, a virus, or other operative expression vector.

Such expression systems, especially where part of an expression vehicle, will commonly require some promoter region that may include a promoter different from that normally associated *in vivo* with the genes coding for the gene expression products and proteins disclosed according to the present invention. Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers. Two appropriate vectors are pKK232-8 and pCM7. Particular named bacterial promoters include *lacI*, *lacZ*, T3, T7, *gpt*, *lambda P<sub>R</sub>*, and *trc*. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.

In a further embodiment, the present invention relates to host cells containing the above-described construct(s). The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a procaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE, dextran mediated transfection, or electroporation (Davis, L., Dibner, M., Battey, L., Basic Methods in Molecular Biology, 1986) .

The constructs in host cells can be used in a conventional manner to produce the gene product coded by the recombinant sequence. Alternatively, the encoded polypeptide, once the sequence is known from the cDNAs, or from isolation of the pure product, can be synthetically produced by conventional methods of peptide synthesis, either manual or automated.

Thus, in accordance with the present invention, once the coding sequence is known, or the gene is cloned which encodes the polypeptide, conventional techniques in molecular biology can be used to

obtain the polypeptide. More generally, the present invention includes all polypeptides coded for by any and each of the DNA or RNA sequences disclosed herein, including fragments of said polypeptides, as well as derivatives and functional analogs thereof.

5

At the simplest level, the amino acid sequence can be synthesized using commercially available peptide synthesizers. This is particularly useful in producing small peptides and fragments of larger polypeptides. (Fragments are useful, for example, in generating antibodies  
10 against the native polypeptide.)

Alternatively, the DNA encoding the desired polypeptide can be inserted into a host organism and expressed. The organism can be a bacterium, yeast, cell line, or multicellular plant or animal. The literature  
15 is replete with examples of suitable host organisms and expression techniques. For example, polynucleotide (DNA or mRNA) can be injected directly into muscle tissue of mammals, where it is expressed. This methodology can be used to deliver the polypeptide to the animal, or to generate an immune response against a foreign polypeptide. Wolff, et al.,  
20 Science, 247:1465 (1990); Felgner, et al., Nature, 349:351 (1991). Alternatively, the coding sequence, together with appropriate regulatory regions (i.e., a construct), can be inserted into a vector, which is then used to transfect a cell. The cell (which may or may not be part of a larger organism) then expresses the polypeptide.

25

The present invention further relates to polypeptides having an amino acid sequence selected from SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 29, as well as fragments, analogs and derivatives of such polypeptide.

30

The terms "fragment," "derivative" and "analog," when referring to the polypeptides disclosed herein also mean polypeptides that

retain essentially the same biological function or activity as said polypeptides. Thus, an analog includes a proprotein which can be activated by cleavage of the proprotein portion to produce an active mature polypeptide. Such fragments, derivatives and analogs must have sufficient  
5 similarity to the polypeptides disclosed herein so that activity of the native polypeptide is retained.

The polypeptides of the present invention may be recombinant polypeptides, natural polypeptides or synthetic polypeptides, preferably  
10 recombinant polypeptides.

"Recombinant," as used herein, means that a protein is derived from recombinant (e.g., microbial or mammalian) expression systems. "Microbial" refers to recombinant proteins made in bacterial or  
15 fungal (e.g., yeast) expression systems. As a product, "recombinant microbial" defines a protein essentially free of native endogenous substances and unaccompanied by associated native glycosylation. Protein expressed in most bacterial cultures, e.g., E. coli, will be free of glycosylation modifications; protein expressed in yeast will have a  
20 glycosylation pattern different from that expressed in mammalian cells.

The fragment, derivative or analog of a polypeptide of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 29 may be (i) one in which one or more of the amino acid residues are substituted with a  
25 conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the mature polypeptide is fused with another compound, such as a  
30 compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the mature polypeptide, such as a leader or secretory sequence or

a sequence which is employed for purification of the mature polypeptide or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the abilities of those skilled in the art in view of the teachings herein.

5

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are purified to homogeneity. When applied to polypeptides, the term "isolated" has its already stated meaning.

10

The polypeptides of the present invention include the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 29, in particular the mature polypeptide, as well as polypeptides which have at least 70% identity to these polypeptides, or which have, at least 90% identity to these polypeptides, still more preferably at least 95% identity to these polypeptides and also include portions of such polypeptides with such portion generally containing at least 30 amino acids and more preferably at least 50 amino acids.

20

Fragments or portions of the polypeptides of the present invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, the fragments may be employed as intermediates for producing the full-length polypeptides. Fragments or portions of the polynucleotides of the present invention may be used to synthesize full-length polynucleotides of the present invention.

25

The present invention also relates to vectors which include polynucleotides of the present invention, host cells which are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques.

30

Host cells are genetically engineered (transduced or

transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector or an expression vector, either of which may be in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media  
5 modified as appropriate for activating promoters, selecting transformants or amplifying the genes of the present invention. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

10 The polynucleotides of the present invention may be employed for producing polypeptides by recombinant techniques. Thus, for example, the polynucleotide may be included in any one of a variety of expression vectors for expressing a polypeptide. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40;  
15 bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. However, any other vector may be used as long as it is replicable and viable in the host.

20 In accordance with the present invention, an appropriate DNA sequence or segment may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into the appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in  
25 the art.

The DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (for example, a promoter sequence) to direct mRNA synthesis. As representative examples  
30 of such promoters, there may be mentioned: LTR or SV40 promoter, the *E. coli. lac* or *trp*, the phage lambda P<sub>L</sub> promoter and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their

viruses. The expression vector also contains a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression.

5 In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.

10

The vector containing the appropriate DNA sequence as hereinabove described, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the protein.

15

As representative examples of appropriate hosts, there may be mentioned: bacterial cells, such as E. coli, Streptomyces, Salmonella typhimurium; fungal cells, such as yeast; insect cells such as Drosophila S2 and Spodoptera Sf9; animal cells such as CHO, COS or Bowes melanoma; 20 adenoviruses; plant cells, etc. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.

25 "Recombinant expression vehicle or vector" refers to a plasmid or phage or virus or vector, for expressing a polypeptide from a DNA (RNA) sequence. The expression vehicle can comprise a transcriptional unit comprising an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers, (2) a structural or coding sequence which is 30 transcribed into mRNA and translated into protein, and (3) appropriate transcription initiation and termination sequences. Structural units intended for use in yeast or eukaryotic expression systems preferably

include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, where recombinant protein is expressed without a leader or transport sequence, it may include an N-terminal methionine residue. This residue may or may not be subsequently cleaved from the expressed recombinant protein to provide a final product.

"Recombinant expression system" means host cells which have stably integrated a recombinant transcriptional unit into chromosomal DNA or carry the recombinant transcriptional unit extra chromosomally. The cells can be prokaryotic or eukaryotic. Recombinant expression systems as defined herein will express heterologous protein upon induction of the regulatory elements linked to the DNA segment or synthetic gene to be expressed.

Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by *Sambrook, et al., Molecular Cloning: A Laboratory Manual*, Second Edition, (Cold Spring Harbor, N.Y., 1989), Wu et al, *Methods in Gene Biotechnology* (CRC Press, New York, NY, 1997), and *Recombinant Gene Expression Protocols*, in *Methods in Molecular Biology*, Vol. 62, (Tuan, ed., Humana Press, Totowa, NJ, 1997), the disclosures of which are hereby incorporated by reference.

Transcription of the DNA encoding the polypeptides according to the present invention by higher eukarotes can be increased by insertion of an enhancer sequence into the vector. Such enhancers have been known for some time and are usually cis-acting elements of DNA, usually anywhere from 10 to 300 bp that act on a promoter to

increase transcription. Common examples include the SV40 enhancer, the cytomegalovirus early promoter enhancer, the polyoma enhancer and the enhancers found in adenovirus.

5                   Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of *E. coli* and *S. cerevisiae* TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence. Such promoters can  
10 be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK),  $\alpha$ -factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing  
15 secretion of translated protein into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.

20                   Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will  
25 comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host. Suitable prokaryotic hosts for transformation include *E. coli*, *Bacillus subtilis*, *Salmonella typhimurium* and various species within the genera *Pseudomonas*, *Streptomyces*, and  
30 *Staphylococcus*, although others may also be employed as a matter of choice.

As a representative but nonlimiting example, useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and GEM 1 (Promega Biotec, Madison, WI, USA). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed.

Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is derepressed by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period. Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.

Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, Cell, 23:175 (1981), and other cell lines capable of expressing a compatible vector, for example, the C127, 3T3, CHO, HeLa and BHK cell lines. Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early promoter, enhancer, splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements.

Recombinant protein produced in bacterial culture is conveniently isolated by initial extraction from cell pellets, followed by one or more salting-out, aqueous ion exchange or size exclusion chromatography steps. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps. Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents.

10

The protein, its fragments or other derivatives, or analogs thereof, or cells expressing them, can be used as an immunogen to produce antibodies thereto. These antibodies can be, for example, polyclonal, monoclonal, chimeric, single chain, Fab fragments, or the product of an Fab expression library. Various procedures known in the art may be used for the production of polyclonal antibodies.

Antibodies generated against the polypeptide corresponding to a sequence of the present invention can be obtained by direct injection of the polypeptide into an animal or by administering the polypeptide to an animal, preferably a nonhuman. The antibody so obtained will then bind the polypeptide itself. In this manner, even a sequence encoding only a fragment of the polypeptide can be used to generate antibodies binding the whole native polypeptide. Such antibodies can then be used to isolate the polypeptide from tissue expressing that polypeptide. Moreover, a panel of such antibodies, specific to a large number of polypeptides, can be used to identify and differentiate such tissue.

For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler and Milstein, 1975, *Nature*, 256:495-497), the trioma technique, the human B-cell

hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole, et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).

5

Techniques described for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce single chain antibodies to immunogenic polypeptide products of this invention.

10

The antibodies can be used in methods relating to the localization and activity of the protein sequences of the invention, e.g., for imaging these proteins, measuring levels thereof in appropriate physiological samples and the like.

15

In carrying out the procedures of the present invention it is of course to be understood that reference to particular buffers, media, reagents, cells, culture conditions and the like are not intended to be limiting, but are to be read so as to include all related materials that one of ordinary skill in the art would recognize as being of interest or value in the particular context in which that discussion is presented. For example, it is often possible to substitute one buffer system or culture medium for another and still achieve similar, if not identical, results. Those of skill in the art will have sufficient knowledge of such systems and methodologies so as to be able, without undue experimentation, to make such substitutions as will optimally serve their purposes in using the methods and procedures disclosed herein.

20

25

30

Specific embodiments of the invention will now be further described in more detail in the following non-limiting examples and it will be appreciated that additional and different embodiments of the teachings of the present invention will doubtless suggest themselves to those of

skill in the art and such other embodiments are considered to have been inferred from the disclosure herein.

5

### EXAMPLE

The proteins encoded by the nucleotide sequences of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 28 are expressed in U2OS cells. This is achieved by selectively PCR amplifying the coding regions thereof (based on the available open reading frames) and then cloning the resulting amplicon into a suitable mammalian expression vector. One such vector is pcDNA3.1 (sold by Invitrogen - #K4800-01). The expression of the protein encoded by the described polynucleotide sequence is detected in either of two ways: by use of specific antibodies raised against peptides derived from the amino acid sequence or by use of antibodies against tags added during the cloning procedure. Examples of such tags are the V5 epitope or a poly-histidine sequence as contained in the pcDNA3.1 vector. In order to accomplish this, cells will normally be transfected with the expression construct and cultured for 1 to 5 days. Cells will then be lysed and their protein content analyzed by western blotting using the above antibodies as appropriate. Cells will also be analyzed for the subcellular localization of the protein encoded by the described polynucleotide sequence by transfecting cells in suitable chambers, culturing them for 1 to 5 days and fixing them *in situ*. Such cells will then be analyzed for the presence and localization of the encoded protein by staining cells with the above-referenced antibodies. Alternatively, cells will be transfected with an expression system in which the protein encoded by the described polynucleotide sequence is fused to a directly detectable tag such as green fluorescent protein (GFP). The expression and localization of the protein encoded by the described polynucleotide sequence is then detected by analyzing that of GFP.

For purposes of identification of the polypeptides disclosed herein, each such polypeptide is listed in the table below along with its calculated molecular weight (Daltons) and its expected isoelectric point (pI).

5 Table 1.

	<u>SEQ ID NO:</u>	<u># Residues</u>	<u>Mol. Wt.</u>	<u>pI</u>
	2	410	45786.9	8.96
10	4	227	26152.3	8.48
	6	275	30781.6	10.00
	10	84	8913.2	9.35
	12	281	30386.7	9.35
	14	322	32977.3	9.27
15	16	141	16444.4	9.34
	18	219	24418.4	9.07
	22	56	6356.3	7.85
	24	344	37375.6	5.82
	26	208	23864.9	9.71
20	29	531	60,576.6	9.63

The polypeptides of SEQ ID NOS: 8 and 20 corresponded only to partial sequences and thus no values could be calculated and such sequences are not in the table.

25

All of the polynucleotides from which these polypeptide sequences are derived are cDNAs isolated during a differential screen of osteogenic mesenchymal stem cells (MSCs) cultured for 4 days in the presence of osteogenic supplements.

30

## SEQUENCE LISTING

<110> Van Den Boss, Christian  
Mbalaviele, Gabriel

<120> Human Mesenchymal DNAs and Expression Products

<130> 640100-363

<140>  
<141>

<150> 60/127,418  
<151> 1999-04-01

<150> 60/148,800  
<151> 1999-08-13

<160> 29

<170> PatentIn Ver. 2.1

<210> 1  
<211> 1974  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:cDNA derived  
from human mesenchymal stem cells after treatment  
with growth supplement

<400> 1  
ggcacgagca gaacaagttt ggctgtcac tgctctcat cctcctgagc cgtgggtaag 60  
acctacagag ttacagacct gctacagaat caacacaaaa taatcagtg acggagggtga 120  
tgttcatggc aacaacagaaa cttctgcgga ttccccaagc agccctggcc aagccaatct 180  
ctatacctac aaacctagtg tccctctttt ctgcgtatgt tgaccggcag aaactgaaact 240  
tgctggagac aaaactgcag ctagtgcagg ggatacgata aaagatctcc aaatgtgtcc 300  
tgtacctctc ttggctgcc acctgcactg ctgccatcac caatggagtg ttttaaatga 360  
gggaaggaag gtactgtttt ccccaaaagca aagtcttgtg ggatcgattc ctgtttacag 420  
gggtgtcttc tctaaatgtc agatatttcc ccaactgctc atgaaatttg gctgggtgat 480  
actctgtctg gttctcttac cttctgtgtt acagtcttgc atgtctact tttactcagt 540  
tctgttttgc atttctcttg cctagagac acaagtgtaa tctctcctt tateccctca 600  
ctactccacc tcagagttaga ttgtagcctg ccaaaggatt ccttccctca tctattgaa 660  
gtgtgttttt cattgcccca tattaatatg actatagaag agccaattaa gtgaatcaa 720  
gatacacaca cacacataga tacacacaca cacaccccat acatgtattt atgtggctct 780  
cagaggggtc ttaaagaatg aatttttagt tgaaaaaaat ttagtgtctc cattacctct 840  
tctaaacaca aaccagctga tgtattttta tctgtttctg tctatcttg taattaattt 900  
ggtgggttct acttgtttta acataaataa agagtatgca gcacgtttta taaaatcaga 960  
actcttaatt ggcttatgcc cagggtctagg ctgagaagtc ctttttcttc ttcccaacct 1020  
tatttcttta gttctgtgcc accttaaatg aaacaacaca tggttatgtc tttttctgtc 1080  
tacaactaca gggtacttga gccttccccc tcaagtgcac tggaaagtcac ccaggatgat 1140  
cctcactagt agcctgcttt ggacgtgtgg ctttttgac acttgccctg tcttctcagat 1200  
actactcag taagcactgc ttcctctctc cccactttta tttgggtgtca tgaatagaaa 1260  
cttccaaatg taaccatgga agctaagttt ggctgtgttt gctttttagt ctccacacca 1320  
tgggcagaaac tgctgtcttt actacttcat ctaccccagg tcccggtccc agggcagccag 1380  
gggcctgggt ttgaataatt gcagggccag cctgcatatg tcttctctac ttaactctct 1440  
cccattcagc aatcaaccag actaaggagt ttgatccct agtgattaca gccctgaaga 1500  
aaattaaatc tgaattaat ttacatggcc ttctgtatct tctctgtgtt cttacttttt 1560  
cgaatgtagt tgggggtgtg gagggacagg ttatgtatt taaagagaat aaacattttg 1620  
cacatacatg tatgtacaa cagtaagatc ctctgttaa accagctgtc ctgttctcca 1680

```

tctccatttc ttcccatgct gtaaccccag gctccaccag ctgttcccca gtgatgttac 1740
ctagcttccc tctaccgttg tctactgacc atttccacta catgcctttc ctaccttccc 1800
ttcacaaaca atcaagtgaat tacttgatta ttatctcttc cttactgtgc tttatctttt 1860
ttgtttggat tggttctaat taatgaaaat aaaagtttct aaatttcat ttttataggg 1920
tattgtaaat aaaaacaaat tgtatactta aaaaaaaaaa aaaaaaaa 1974

```

&lt;210&gt; 2

&lt;211&gt; 410

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Putative  
protein derived from ORF cDNA of SEQ ID NO:1

&lt;400&gt; 2

```

Met Glu Leu Pro Ser Gly Pro Gly Pro Glu Arg Leu Phe Asp Ser His
  1                      5                      10                      15

```

```

Arg Leu Pro Gly Asp Cys Phe Leu Leu Leu Val Leu Leu Leu Tyr Ala
      20                      25                      30

```

```

Pro Val Gly Phe Cys Leu Leu Val Leu Arg Leu Phe Leu Gly Ile His
      35                      40                      45

```

```

Val Phe Leu Val Ser Cys Ala Leu Pro Asp Ser Val Leu Arg Arg Phe
      50                      55                      60

```

```

Val Val Arg Thr Met Cys Ala Val Leu Gly Leu Val Ala Arg Gln Glu
      65                      70                      75                      80

```

```

Asp Ser Gly Leu Arg Asp His Ser Val Arg Val Leu Ile Ser Asn His
      85                      90                      95

```

```

Val Thr Pro Phe Asp His Asn Ile Val Asn Leu Leu Thr Thr Cys Ser
      100                      105                      110

```

```

Thr Pro Leu Leu Asn Ser Pro Pro Ser Phe Val Cys Trp Ser Arg Gly
      115                      120                      125

```

```

Phe Met Glu Met Asn Gly Arg Gly Glu Leu Val Glu Ser Leu Lys Arg
      130                      135                      140

```

```

Phe Cys Ala Ser Thr Arg Leu Pro Pro Thr Pro Leu Leu Leu Phe Pro
      145                      150                      155                      160

```

```

Glu Glu Glu Ala Thr Asn Gly Arg Glu Gly Leu Leu Arg Phe Ser Ser
      165                      170                      175

```

```

Trp Pro Phe Ser Ile Gln Asp Val Val Gln Pro Leu Thr Leu Gln Val
      180                      185                      190

```

```

Gln Arg Pro Leu Val Ser Val Thr Val Ser Asp Ala Ser Trp Val Ser
      195                      200                      205

```

```

Glu Leu Leu Trp Ser Leu Phe Val Pro Phe Thr Val Tyr Gln Val Arg
      210                      215                      220

```

```

Trp Leu Arg Pro Val His Arg Gln Leu Gly Glu Ala Asn Glu Glu Phe
      225                      230                      235                      240

```

Ala Leu Arg Val Gln Gln Leu Val Ala Lys Glu Leu Gly Gln Thr Gly  
245 250 255

Thr Arg Leu Thr Pro Ala Asp Lys Ala Glu His Met Lys Arg Gln Arg  
260 265 270

His Pro Arg Leu Arg Pro Gln Ser Ala Gln Ser Ser Phe Pro Pro Ser  
275 280 285

Pro Gly Pro Ser Pro Asp Val Gln Leu Ala Thr Leu Ala Gln Arg Val  
290 295 300

Lys Glu Val Leu Pro His Val Pro Leu Gly Val Ile Gln Arg Asp Leu  
305 310 315 320

Ala Lys Thr Gly Cys Val Asp Leu Thr Ile Thr Asn Leu Leu Glu Gly  
325 330 335

Ala Val Ala Phe Met Pro Glu Asp Ile Thr Lys Gly Thr Gln Ser Leu  
340 345 350

Pro Thr Ala Ser Ala Ser Lys Phe Pro Ser Ser Gly Pro Val Thr Pro  
355 360 365

Gln Pro Thr Ala Leu Thr Phe Ala Lys Ser Ser Trp Ala Arg Gln Glu  
370 375 380

Ser Leu Gln Glu Arg Lys Gln Ala Leu Tyr Glu Tyr Ala Arg Arg Arg  
385 390 395 400

Phe Thr Glu Arg Arg Ala Gln Glu Ala Asp  
405 410

&lt;210&gt; 3

&lt;211&gt; 1619

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:cDNA derived  
from human mesenchymal stem cells after treatment  
with growth supplement

&lt;400&gt; 3

```

ggcacgaggc gccctctcct tgcctctggt ggcgtgtgcc ttgctccccc tgtgcgggaa 60
aagaatccag gcccttcac gcgcgtgtgt gtgcgggggc ccgcaagtgc tegtgtgttc 120
ccgctagggtc tccgctgggg caggaaaccgg aatcatccggg gggaccacca gcaccgccgc 180
ggtcaccttc gaggcggagc agaatgagaa catcaccctgt gtgaaggcca tccgcgtctc 240
ggaaaatgtg attgatcgaa tgaaggaaatc ctctccatct ggttcgaagt ctcagcggta 300
ttctggtgct tatggtgcct cagtttctga tgaagaattg aaaagaagag tagctgagga 360
gctggcattg gagcaagcca agaaaagaatc cgaagatcag aaacgactaa agcaagccaa 420
agagctggac cgagagaggg ctgctgccaa tgagcagtta accagagcca tccttcggga 480
gaggatatgt agcgaggagg aacgcgctaa ggcaaacgac ctggctatggc agctggaaga 540
gaaagaccga gtgctaagaa agcaggatgc attctacaaa gaacagctgg ctgactgga 600
ggagaggagc tcagagtctc acagagtcac cactgaacaa tatcagaaga ctgctgaaga 660
gtggaagcaa agttcaagcg atatgagtct catccagtct gtgctgatct gcaggccaaa 720
attcttcagt gttaccgtga gaacacccac cagaccctca aatgctccgc tctggccacc 780
cagtatatgc actgtgtcaa tcattgccaa cagagcatgc ttgagaaggg aggataaaaa 840
ctttcagaat gagcaaaaac ccatcaacgt taattccaga gatggaacat ttttttctct 900

```

```

<210> 4
<211> 227
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Putative
protein derived from ORF of cDNA of SEO ID NO: 3.

```

4

195

200

205

Thr Gln Tyr Met His Cys Val Asn His Ala Lys Gln Ser Met Leu Glu  
210 215 220

Lys Gly Gly  
225

<210> 5  
<211> 1917  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:cDNA derived  
from human mesenchymal stem cells after treatment  
with growth supplement

<400> 5  
ggcacgagga gagaggtggt gaaactcaag atccccatgg acaacaagga ggtcccgggc 60  
gaggcgcccg cgcgctcccg cgaccggcg cgccccacg cgtgccccga ctgcggccgc 120  
gccttcgagc gccgctccac gctggcggaag cacgcgcgca cgcacacggg cgaacggccc 180  
ttcgggtgca ccgagtgcgg gcggcgcttc tcacagaagt cgcgctgac caaacacggc 240  
cgacgcaca cgggcgagcg gccctacgag tgccccgagt gcgacaaacg cttctcgccc 300  
gcctcgaaac ttggcgagca ccgacggcgg cacacggggc agaagccgta cgcgatcgcg 360  
cactgcggcc gccgcttcgc gcagagctcc aactacgcac agcacctggc cgtgcacacg 420  
ggcgagaagc cgtacgcgtg ccggaactgc ggaacgcgct ttggcgccag ctcgctgctg 480  
gcgcgccacc gacgcacgca cacggcgag cggccctacg cttgcgccga ctgcggcaac 540  
cgcttcgctc agagctcgcg gctggccaaag caccggcgcg tgacacacgg cgagaagccg 600  
caccgctgcg ctgtgtgtgg ccgtcgcttc ggccaccgct ccaacctggc ggagcacgcg 660  
cgacgcaca caggcgagcg gccctacccc tgcccgagt gcggcccgccg cttccgccta 720  
agctcgcaat tcattcgcca ccgacgcgcg cacatgcggc gccgacctga tatttgccgc 780  
ggctgcggca ggaactcaaa gctgccccc ggcccgacg ccgccaactg caccgagctc 840  
tgcccgaggt gtgaggggcag ctgagtcocg cagggctcgg gaggggcgcg ctggggcttc 900  
gacctggctg cactaaccca ggctcctcct cgccccggcc tccgggtctg ggaaattgag 960  
gggacggcag gcccgctgc cctggaactg ggagacaggg agaattccct gccgggggtcc 1020  
ctggaaacag tgcocacccc acatcactac attcctcgg cccgtgttag tgaataaagt 1080  
attatatcct caccaccacc gtgcctgtga gtgaggtggg tgggagagga agaaagtggg 1140  
ggttctccag gctcaggtgc caagtgaagt gtcaaggaaac caaatgggga tgtaaaacct 1200  
aaagggggttc ccggcacctc ggttgtgttt gtttggaggt gatcgacac ttggcccttg 1260  
gttagctcct cattaacctta gacctgaaag ggccataaaa tatactatgt tcacgatcag 1320  
acacgcactg cattcgagcg agctccagtg agcaaggcac gacctcaga tctcagctca 1380  
gtgagggaga gaaaactgta ataactacac gttaaagggt ttaactgctt tggtagttaa 1440  
gcttaccocg ccggcgcgac agtgactcac gcctgtaatc ccagcacttt gggagggcga 1500  
ggctagcaga tcaacttgagg ttaggagttc gataccagcc tggccaacat ggtgaaaccc 1560  
ggctctcact aaaaatacaa aaattaactg ggtgtgtgg cgggcgcttg taatcccgag 1620  
tactgagggg gctgaggcat gagaataact tgaacctggg agacagaggt tgcaatgaac 1680  
cgagatagtg ccattgcaat ccggcctggg caacagagga agactgcctc aaacaaacaa 1740  
aaaacaacaa accaaaccaa accaaaaaaa tctcaagcg attggacctg gcagctcatg 1800  
cctgtaatct ccagcacttt gggaggcgga ggcaggagga tctcttgaag tcaagagttt 1860  
gagatcagcc tggagaacaa agtgagaccc catctatata aaaaaaaaaa aaaaaaa 1917

<210> 6  
<211> 275  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Putative

protein derived from ORF of cDNA of SEQ ID NO: 5.

```

<400> 6
Met Asp Asn Lys Glu Val Pro Gly Glu Ala Pro Ala Pro Ser Ala Asp
 1              5              10              15

Pro Ala Arg Pro His Ala Cys Pro Asp Cys Gly Arg Ala Phe Ala Arg
      20              25              30

Arg Ser Thr Leu Ala Lys His Ala Arg Thr His Thr Gly Glu Arg Pro
      35              40              45

Phe Gly Cys Thr Glu Cys Gly Arg Arg Phe Ser Gln Lys Ser Ala Leu
 50              55              60

Thr Lys His Gly Arg Thr His Thr Gly Glu Arg Pro Tyr Glu Cys Pro
 65              70              75              80

Glu Cys Asp Lys Arg Phe Ser Ala Ala Ser Asn Leu Arg Gln His Arg
      85              90              95

Arg Arg His Thr Gly Glu Lys Pro Tyr Ala Cys Ala His Cys Gly Arg
      100             105             110

Arg Phe Ala Gln Ser Ser Asn Tyr Ala Gln His Leu Arg Val His Thr
      115             120             125

Gly Glu Lys Pro Tyr Ala Cys Pro Asp Cys Gly Arg Ala Phe Gly Gly
      130             135             140

Ser Ser Cys Leu Ala Arg His Arg Arg Thr His Thr Gly Glu Arg Pro
      145             150             155             160

Tyr Ala Cys Ala Asp Cys Gly Thr Arg Phe Ala Gln Ser Ser Ala Leu
      165             170             175

Ala Lys His Arg Arg Val His Thr Gly Glu Lys Pro His Arg Cys Ala
      180             185             190

Val Cys Gly Arg Arg Phe Gly His Arg Ser Asn Leu Ala Glu His Ala
      195             200             205

Arg Thr His Thr Gly Glu Arg Pro Tyr Pro Cys Ala Glu Cys Gly Arg
      210             215             220

Arg Phe Arg Leu Ser Ser His Phe Ile Arg His Arg Arg Ala His Met
      225             230             235             240

Arg Arg Arg Leu Tyr Ile Cys Ala Gly Cys Gly Arg Asp Phe Lys Leu
      245             250             255

Pro Pro Gly Ala Thr Ala Ala Thr Ala Thr Glu Arg Cys Pro Glu Cys
      260             265             270

Glu Gly Ser
      275

```

<210> 7

<211> 1150

<212> DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:cDNA derived  
from human mesenchymal stem cells after treatment  
with growth supplement

&lt;400&gt; 7

```

ggcacgagct gcggaataac ttcccgctca gcacatcacc tcaaatgtga tctgcgagtg 60
cacacaggcg agcgggcccta caagtgtccg cactgcgact acgcgggcac ccaagtccggc 120
tcgtccaagt atcacctaca gcgccaccac cgggagcaga ggagcggggc cggcccgggg 180
ccacccccgg agccaccgcc tccttcccag cggggttcgg ccccgcaatc tggagccaag 240
ccgtctccgc agcctcgac ctgggtggag ggcgcctcaa gtccccggcc tccttctagc 300
ggtgctgggc cggggtcccg tcggaagccc gccagcccct ggaggaccct gcgcaacggg 360
cgaggcgggt aggcgaaccc cctggacctg tccttgccgg cagggccggg aggcgagggc 420
gggctggggg gtgcctcca ccgctgcctc ttctgcccgt tcgccactgg agcccagag 480
ctcatggcct tgcaccttca agtgcaccac agccgcccgg ctaggggccc cgggccacc 540
caggctgacg cgtccccgc ctatgcccga gtaccatcag gagagacccc tcccagtcct 600
tcgcaggaag gggaggaggg ctccgggctg tccagacccc gagaggcagg gctggggggg 660
caagaacggt agtgggccc cagggcgcat tagcttagtg agcttaccoc gccggagcgg 720
gggagcgcta gaggtagtgt ggtagagaag ccagcagggg gcagcgtggg acccatatcc 780
cagcccccag cgaaccagag gtggaaggcg cggcgggcgt agggaggtgg gctggcggtta 840
cccaccagc ccaagggagt cacagtgcct tagaagtggc agaggtaggg tcaagaacg 900
gggtccctgg gctggcagag aaggtttgtg tccctgttga ggagccact tgccagttct 960
tgctgttcca taggcgtgag agtttatatt tgtacaaggg gtgagcgttg ggggcactgt 1020
accctttagc ccccatcagg ggcctcttag acgtcgtgat ttttggtacg attcctgtca 1080
tccctattgc agagtctgt ccccaataaa caggtgtcct gaggcacagg aaaaaaaaaa 1140
aaaaaaaaaa                                     1150

```

&lt;210&gt; 8

&lt;211&gt; 100

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Putative  
protein derived from ORF of cDNA of SEQ ID NO: 7.

&lt;400&gt; 8

```

Ile Arg His Glu Leu Arg Lys Ile Phe Pro Leu Ser Thr Ser Pro Gln
 1             5             10             15

Ser Ala Ser Ala Ser Ala His Arg Arg Ala Ala Leu Gln Val Ser Ala
      20             25             30

Leu Arg Leu Arg Gly His Pro Val Arg Leu Ala Gln Val Ser Pro Thr
      35             40             45

Ala Pro Pro Pro Gly Ala Glu Glu Arg Gly Arg Pro Arg Ala Thr Pro
      50             55             60

Gly Ala Thr Glu Ala Ser Phe Pro Ala Gly Phe Gly Pro Ala Ile Trp Ser
      65             70             75             80

Gln Ala Val Ser Ala Ala Cys Asp Leu Gly Gly Gly Arg Leu Lys Ser
      85             90             95

Pro Ala Ser Phe
      100

```

<210> 9  
 <211> 1573  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:cDNA derived  
 from human mesenchymal stem cells after treatment  
 with growth supplement

<400> 9  
 ggcacgaggt ggggtgcacg ctcccccca tccccatcgg cctgtcccc tggagtgtgt 60  
 cagagcccag gggagaatgc agcccaccag gagcacctgg accccctgcc cgccacatgg 120  
 tgtggccatc actcagcccc taccctcgcc ctgctcctaa gggtagaaaa ctccagggtc 180  
 cctgccacc gactgccag ccactccaag cccctggca gctgccctc ctggagcaga 240  
 aagtgccttt atctcagcca tcgcagact gctcgccag atcgggggac aggtctggaat 300  
 gagggaggcg tcttcacttc cctgccatcc cctctcacc ccacccccg cccaccggg 360  
 ctgcagggtg tgcctgatcg ctgggatctg attgaggata aaaaggaagg agagatgacc 420  
 cctaccccc catccccag ttttgaaaag gtctaagcaa gtgagtctgg tggaggagct 480  
 gagggaggga gccatggaag gtgccagaag gaaggttgcc gggggcacgt gtgggcccgtg 540  
 gcttgggctg gtccagagtg cgtgagctgc ccggcgccgt ccttgcccaa gtgaccaggg 600  
 aagtgtgtgt gtgtccatgt gtatgcgtgt ccgtctgtct gtctagtgtc tgggtttggc 660  
 ccaagactgg cctgtagtta cattaatgcc cagccagcca cccctgccac tcaccctcc 720  
 tggccaggcg gtgtcctgact ctctgagctg agggcaggcg agcctgaact 780  
 tgttgatcta cccgtgcctg ggcctctccc ctccagagccc atggtaacga accctagaa 840  
 aggagaagaac gggcgtcagg ggtgcacagt ccacagctga agagcaaggt ttctgtggcag 900  
 cacggcccg ggcctcacc tctgtcccca cgaggggacc catgggggct gctcttgacg 960  
 ggcacagatg accaaagtcc ctctctgctt cctgttacct gtcttgcctc tggggagaaa 1020  
 gaggggctcg atgagactcc actcagggtgc acacatcacc aggtgcatct gcaggcactg 1080  
 ggcctggctg ttgcagccag gagaaggcca ggcagaagga gtgtatgagt gtgagtgtgt 1140  
 gtgcattgaa gttggggcac tgggcgtctg actccctccc caccacaagag aggaaggacc 1200  
 cctcaccacc cccactggcg agacagttaa ctttgcggac ttgccatggt tttgccaaaa 1260  
 ccaagatttt gaaggaatag agtggccagc gccaggcgcc agggccatgt gctgcgccag 1320  
 cctcaatgtc acttggtggc ggggtggggt ggggtggggc agcagcatcc cagccttgag 1380  
 atgcttcaat tctcttctct gtaaccagac tttgaaaaat tgtctgtttc atcaggctct 1440  
 gttcctcaat ggccttttgc tacgtgcctc ccgagaaatt tgtctttttg tataaatgac 1500  
 aaagtgttga aaatgtattt cctgaataaa atgtttcaaa tgcagaaacc caaaaaaaa 1560  
 aaaaaaaaa aaa 1573

<210> 10  
 <211> 84  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:Putative  
 protein derived from ORF of cDNA of SEQ ID NO: 9.

<400> 10  
 Met Ser Val Ser Val Cys Ala Trp Lys Leu Gly His Trp Ala Ser Asp  
 1 5 10 15  
 Ser Leu Pro Thr Gln Glu Arg Lys Asp Pro Ser Pro Pro Pro Leu Ala  
 20 25 30  
 Arg Gln Phe Thr Leu Pro Thr Cys His Val Phe Ala Lys Thr Lys Ile  
 35 40 45  
 Leu Lys Glu Met Ser Gly Gln Arg Gln Gly Pro Gly His Val Ala Cys

50

55

60

Pro Ala Ser Met Ser Leu Gly Gly Gly Val Gly Trp Gly Trp Ala Ala  
 65 70 75 80

Ala Ser Gln Pro

&lt;210&gt; 11

&lt;211&gt; 1808

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:cDNA derived  
 from human mesenchymal stem cells after treatment  
 with growth supplement

&lt;400&gt; 11

ggcagcaggc cgcccgccg agcgcggagc gcagccactc gcgcgtgcc agggagcgcc 60  
 caagatgtgg ggggacccgg gcggcagcgg ccgtagcagc gccagggagc ggggcaacgca 120  
 gcagcctccg ctgcgccggc tgtcctgacc tgctcgtctt gcccccaaa aatgtcagcc 180  
 aagtccaagg ggaacccctc ctgcctctgt ccagccgagg gaccgccggc agcctccaaa 240  
 accaaggtga aggaacagat caagatcctc gtggaggatt tgggaattagt cctgggcgac 300  
 ctgaaggagc tggccaaggaa acttaaggag atgaagtccc actctgttgc ccaggctaga 360  
 gtgcaattggc acaatctggg ctcaactgcaa cctctgcctc ccaggttcaa gctattctcc 420  
 tgctcagccg tgctcctagt cgccactacg cctgggtggg tgaccagatt gacacccatga 480  
 cctctgacct acagctggag gatgagatga ctgacagctc caaaaacggac acgctgaata 540  
 tagctccaag tggcacaaaca gccctccagc tagaagaagt caaagtgcag gctaatgcac 600  
 cgcttattaa acccccagca caccatctgt ctatctctac ggtcctgaga aagccaaacc 660  
 ctcccaccac tctcccaagg ttgacacctg tgaagtgtga agacccccaa aggggtggtc 720  
 caactgccaa tctgttaaaa accaatggca ccttctacg aaatggaggc ttaccagggtg 780  
 gacctaaaca aattccaatg ggagatatct gtgtctaccc caacagtaac ttggacaagg 840  
 ctccagtcga gcttctgatg catagacctg aaaaagacag atgtccccag gcagggcctc 900  
 gagaacgagtg tcggtttaat gaaaaagtac agtaccatgg ctattgtcct gactgtgata 960  
 cccggtataa cataaaaaac agggagggtcc acttacacag tgaacctgtc cccccaccgg 1020  
 gaaaagattcc tcaccaaggc cctccctccc ctctacaccc ccatctccct cctttcccac 1080  
 tagaaaaatgg ggggaatggga ataagccaca gtaacagctt cccccctatc agacctgcaa 1140  
 ctgtgctccc tcccactgca ccaaaaaccac agaagacgat cttgaggaag tcaaccacta 1200  
 caaccggtgt atgtatgccaa ttaaaaaaat tgttttttta attttctata ttataaacat 1260  
 aaaaataagta atgagcactt tctactcaag caataaaaaa cccaaatata ttaactctgc 1320  
 attcagcaaaa gtggcataaaa aatcacctgg taagtatgca gcacattgtc tatatcctgg 1380  
 gatgacatta ttttaaatgt tgtatcatta aaacacctcag aatgatgaaa aatatgaatg 1440  
 atgcatgtgt tttgcaattg acctatgaca aactgtgaac ctgcaagattt caccattttt 1500  
 gatttactat aagagctggg atttgattca ttttatttat gcctaagtca tctatgactt 1560  
 aacatgtcat attcttaact ttgatctaag gctttttact aggaaatttt aataatgaag 1620  
 gactatttta ttattttttt ctaaaagatgt ttgtcactag tttttcatta ttaaatgctg 1680  
 aggccaatac caagaagttt attttctata ttatacaatt tttaataaca tgctcagcta 1740  
 tatatgtaat aaaatacttt ggtctgtgga aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1800  
 aaaaaaaaaa 1808

&lt;210&gt; 12

&lt;211&gt; 281

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Putative  
 protein derived from ORF of cDNA of SEQ ID NO: 11.

&lt;400&gt; 12

Met Ala Gln Ser Gly Leu Thr Ala Thr Ser Ala Ser Gln Val Gln Ala  
 1 5 10 15

Ile Leu Leu Pro Gln Pro Ala Ser Val Arg His Tyr Ala Trp Val Val  
 20 25 30

Asp Gln Ile Asp Thr Leu Thr Ser Asp Leu Gln Leu Glu Asp Glu Met  
 35 40 45

Thr Asp Ser Ser Lys Thr Asp Thr Leu Asn Ser Ser Ser Ser Gly Thr  
 50 55 60

Thr Ala Ser Ser Leu Glu Lys Ile Lys Val Gln Ala Asn Ala Pro Leu  
 65 70 75 80

Ile Lys Pro Pro Ala His Pro Ser Ala Ile Leu Thr Val Leu Arg Lys  
 85 90 95

Pro Asn Pro Pro Pro Pro Pro Pro Arg Leu Thr Pro Val Lys Cys Glu  
 100 105 110

Asp Pro Lys Arg Val Val Pro Thr Ala Asn Pro Val Lys Thr Asn Gly  
 115 120 125

Thr Leu Leu Arg Asn Gly Gly Leu Pro Gly Gly Pro Asn Lys Ile Pro  
 130 135 140

Asn Gly Asp Ile Cys Cys Ile Pro Asn Ser Asn Leu Asp Lys Ala Pro  
 145 150 155 160

Val Gln Leu Leu Met His Arg Pro Glu Lys Asp Arg Cys Pro Gln Ala  
 165 170 175

Gly Pro Arg Glu Arg Val Arg Phe Asn Glu Lys Val Gln Tyr His Gly  
 180 185 190

Tyr Cys Pro Asp Cys Asp Thr Arg Tyr Asn Ile Lys Asn Arg Glu Val  
 195 200 205

His Leu His Ser Glu Pro Val His Pro Pro Gly Lys Ile Pro His Gln  
 210 215 220

Gly Pro Pro Leu Pro Pro Thr Pro His Leu Pro Pro Phe Pro Leu Glu  
 225 230 235 240

Asn Gly Gly Met Gly Ile Ser His Ser Asn Ser Phe Pro Pro Ile Arg  
 245 250 255

Pro Ala Thr Val Pro Pro Pro Thr Ala Pro Lys Pro Gln Lys Thr Ile  
 260 265 270

Leu Arg Lys Ser Thr Thr Thr Thr Val  
 275 280

&lt;210&gt; 13

&lt;211&gt; 1498

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:cDNA derived  
from human mesenchymal stem cells after treatment  
with growth supplement

&lt;400&gt; 13

```

ggcacgagcg cgactcgggc tccggaccgc ggcaactgtg gcggctggag cggagcgcac 60
cgccgcggtg gtgccacag cgagcgcgag ctccctgccc cgcctccccc cctcggcctc 120
gcggcgacg cgccggtggc ggcttggag actcggagag ccgagtgaa acatttccac 180
ctggacaact gaccatgtgc ctgccctgag cagcgaggcc caccaggcat ctctgtgtgt 240
ggcagcaggg ccagggtcct gtctgtggac cctcggcagt tggcaggctc cctctgcagt 300
ggggtctggg cctcggcccc accatgtcga gctcggcggt tggctccccg gatgccggcg 360
gcagtagcag cagcagcacc aatggcagcg gtggcagtg cagcagtgcc ccaaggcgag 420
gagcagcaga caagagtgcga gtggtggctg ccgccgaccc agcctcagtg gcagatgaca 480
caccaccccc cgagcgtcgg aacaagagcg gtatcatcag tgagccccct aacaaggagcc 540
tgccgcgctc ccgccccctc tcccactact cttcttttgg cagcagtggt ggtagtggcg 600
gtggcagcat gatgggcgga gagtctgctg acaaggccac tgcggtgcga gccgtgctc 660
cctgtttggc caatggcgat gacctggcgg cggccatggc ggtggacaaa agcaacccta 720
cctcaagaca caaaagtgtt gctgtggcca gcctgctgag caaggcagag cgggccacgg 780
agctggcagc cgaggggacag ctgacgctgc agcagtttgc gcagtcacac gagatgctga 840
agcgcgtgtg gcaggagcat ctcccctgta tgagcgaggg ggggtgctggc ctgctgaca 900
tggaggctgt ggcaggtgcc gaagcctca atggccagtc gacttcccc tacctggggc 960
ctttcccatc caacccagcg ctcttcatta tgaccccgcc aggtgtgttc ctggcccgaga 1020
gcgcgctgca catggcgggc ctggctgagt acccatgca gggagagctg gcccttgcca 1080
tcagctccgg caagaagaag cggaacgcgt gcggcatgtg cgcgccctgc cggcgccgca 1140
tcaactgcga gcagtcgacg agttgtagga atcgaaagac tggccatcag atttgcaaat 1200
tcagaaaaat tgaggaactc aaaaagaagc cttccgctgc tctggagaag gtgatgctc 1260
cgacggggagc cgccttcggg tggtttcagt gacggcgggc gaacccaaa ctgccctctc 1320
cgtgcaatgt cactgctcgt gtggtctcca gcaagggatt cgggcgaaga caaacgagc 1380
caccgctctt tagaaccaaa aatatctctc cacagatttc attcctgttt ttatatatat 1440
attttttgt gtcggtttaa catctccacg tccctagcat aaaaaaaaaa aaaaaaaa 1498

```

&lt;210&gt; 14

&lt;211&gt; 361

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:Putative  
protein derived from ORF of cDNA of SEQ ID NO: 13.

&lt;400&gt; 14

```

Met Ser Ser Leu Gly Gly Gly Ser Gln Asp Ala Gly Gly Ser Ser Ser
  1              5              10              15

Ser Ser Thr Asn Gly Ser Gly Gly Ser Gly Ser Ser Gly Pro Lys Ala
      20              25              30

Gly Ala Ala Asp Lys Ser Ala Val Val Ala Ala Ala Pro Ala Ser
      35              40              45

Val Ala Asp Asp Thr Pro Pro Pro Glu Arg Arg Asn Lys Ser Gly Ile
      50              55              60

Ile Ser Glu Pro Leu Asn Lys Ser Leu Arg Arg Ser Arg Pro Leu Ser
      65              70              75              80

His Tyr Ser Ser Phe Gly Ser Ser Gly Gly Ser Gly Gly Ser Met
      85              90              95

```

Met Gly Gly Glu Ser Ala Asp Lys Ala Thr Ala Ala Ala Ala Ala Ala  
100 105 110

Ser Leu Leu Ala Asn Gly His Asp Leu Ala Ala Ala Met Ala Val Asp  
115 120 125

Lys Ser Asn Pro Thr Ser Lys His Lys Ser Gly Ala Val Ala Ser Leu  
130 135 140

Leu Ser Lys Ala Glu Arg Ala Thr Glu Leu Ala Ala Glu Gly Gln Leu  
145 150 155 160

Thr Leu Gln Gln Phe Ala Gln Ser Thr Glu Met Leu Lys Arg Val Val  
165 170 175

Gln Glu His Leu Pro Leu Met Ser Glu Ala Gly Ala Gly Leu Pro Asp  
180 185 190

Met Glu Ala Val Ala Gly Ala Glu Ala Leu Asn Gly Gln Ser Asp Phe  
195 200 205

Pro Tyr Leu Gly Ala Phe Pro Ile Asn Pro Gly Leu Phe Ile Met Thr  
210 215 220

Pro Ala Gly Val Phe Leu Ala Glu Ser Ala Leu His Met Ala Gly Leu  
225 230 235 240

Ala Glu Tyr Pro Met Gln Gly Glu Leu Ala Ser Ala Ile Ser Ser Gly  
245 250 255

Lys Lys Lys Arg Lys Arg Cys Gly Met Cys Ala Pro Cys Arg Arg Arg  
260 265 270

Ile Asn Cys Glu Gln Cys Ser Ser Cys Arg Asn Arg Lys Thr Gly His  
275 280 285

Gln Ile Cys Lys Phe Arg Lys Cys Glu Glu Leu Lys Lys Lys Pro Ser  
290 295 300

Ala Ala Leu Glu Lys Val Met Leu Pro Thr Gly Ala Ala Phe Arg Trp  
305 310 315 320

Phe Gln Lys Thr Lys Ile Leu Lys Glu Met Ser Gly Gln Arg Gln Gly  
325 330 335

Pro Gly His Val Ala Cys Pro Ala Ser Met Ser Leu Gly Gly Gly Val  
340 345 350

Gly Trp Gly Trp Ala Ala Ala Ser Gln  
355 360

&lt;210&gt; 15

&lt;211&gt; 2329

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:cDNA derived  
from human mesenchymal stem cells after treatment

with growth supplement

<400> 15  
 ggcacgagat gacattactc actatcagaa ttgagaaaaa tggtttgaaa gatgctgggc 60  
 agtgcacatga tccctatatt acagttagtg taaaggatct gaatggcgata gacttaactc 120  
 ctgtgcgaaga tactcctgtg gcttcaagaa aagaagatgc atagtgtcat tttaattgtg 180  
 acattgagct ccagaagcat gttgaaaaat taacccaagg tgcagctatc ttctttgaat 240  
 tcaaacacta caagcctaaa aaaagggtta ccagaccacaa gtgttttgct ttcatggaga 300  
 tggatgaaat taaacctggg ccaattgtaa tagaactata caagaaaccc actgacttta 360  
 aaagaagaata attgcaatta ttgaccaaga aaccaattta tcttcattca catcaactct 420  
 tgccacaagga atgatcctga catgatgaac ctggaaacttc tgtgaatttt accactcagt 480  
 agaaaaccatc atgtctctgt gtacgatatt cacccttcaa caggcgccgaa gcaagccgtg 540  
 ccagaccacag tagggccggac ggagtccaat gcaaaagctgt accacagaat tcagagtcca 600  
 gcacatcaca ctgacgtata ggactccttg ggatacaggt ttattgtaga ttttgaaaca 660  
 tgtttttctt ttcttattaa ttgtgcaatt aatagtcctat ttctaatatt accactactc 720  
 ctacctgtct tcctggaaaca atactgttgt ggttaggatg tgcctcatct cagacttaac 780  
 acagcaataa gaatgtgcata gaatttacac atctgttcac ttttgctcca atagtctctt 840  
 ttgacttaac gtcaagcttt gggttgatgt ggttagggta gtgtcaaatc gctttgagag 900  
 gaatgggacc agtttctgtg cctaagaagg tctgtctgga tgtttatagg cagcacctct 960  
 gaagtggcct aaattcaccc tgatctgata gttttcctgc ttgaaaagtg tgccttggcc 1020  
 agatcagtat ccacatggg agtgttccct aggttctgagc tgtgattgtt tccagatgac 1080  
 cagattgttt ttgtgaaaaa gagcataatt tagtcatgt cgattagctg ttcttctaca 1140  
 tcacattgtt actcttctgt atgatgattc tagggttaac attggaacca tctcaaaata 1200  
 attacaaagt ttttagatggg tttaacaagt cttctaaaca atgtaactta aaaaataatt 1260  
 agtcagatgc taacagcata ctgcaggcat aactgctgtt ttctgtacaa ctgattgtga 1320  
 aaaccttaaaa cctgcatacc tcttcttaca gtgaggagata tgcaaaatct ggaagatat 1380  
 tctatttttt tctataaggt agataggatc gccattttat tctatttag atatactgac 1440  
 attcatccat atgaaaaatt gcaggtcatt agcttactat aatttacttt tgaactaatg 1500  
 gggcataaat aaaacttcca tagtacaaga ggtggatatt tgatcacagc aacatttggc 1560  
 gtgggctttc tgtgggttag atgtaaaagc cacatatatt taatattact attttaaatg 1620  
 agcaatgcag ggggggaatg cagtgtcagt acctggccta tttttaaact agtgttaatc 1680  
 cctatgcat accattcaat atgtttgtct tttaaaataa gtaaccacaa ttaagtttgt 1740  
 gtaccccttg cacttcaaga gatctagtct ttactttcag ttgtctgtta ggtccattct 1800  
 gttttactga cggatgttaa taaaaactat gcgagctga atgaattctc agtcaaattt 1860  
 agtcttgctc ctactcttga ttggattaat tccaaattct aaaatgattc agtcacacat 1920  
 agctcctagg gatgaagaat ttgccttact ttgcccagtt ctaagactgt tgaattgtca 1980  
 aatccttaga ctgtaagctc ttcaaggagc aagaggcgca ttttctccgt gtcattgta 2040  
 ttttctaagg tgcctggcag cactctgacc ctgtggagta ccagaccct ttgtttgatg 2100  
 ttgtgcacaa gacctgaaaa aaaatccctt aaaaaaaaac acccattaaa gtgtagcaaa 2160  
 accgatgat tattttttct ctttttctat aaaccataag atagtatat caaaatgata 2220  
 attttatga agcatctgct atccttcaca taagtatagt ttatatgaac tacaatatcc 2280  
 ttcatcaac attaaagaag cttaaatgta aaaaaaaa aaaaaaaa 2320

<210> 16  
 <211> 141  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Putative  
 protein derived from ORF of cDNA of SEQ ID NO: 15.

<400> 16  
 Met Thr Leu Leu Thr Ile Arg Ile Glu Lys Ile Gly Leu Lys Asp Ala  
 1 5 10 15  
 Gly Gln Cys Ile Asp Pro Tyr Ile Thr Val Ser Val Lys Asp Leu Asn  
 20 25 30  
 Gly Ile Asp Leu Thr Pro Val Gln Asp Thr Pro Val Ala Ser Arg Lys

35 40 45

Glu Asp Thr Tyr Val His Phe Asn Val Asp Ile Glu Leu Gln Lys His  
50 55 60

Val Glu Lys Leu Thr Lys Gly Ala Ala Ile Phe Phe Glu Phe Lys His  
65 70 75 80

Tyr Lys Pro Lys Lys Arg Phe Thr Ser Thr Lys Cys Phe Ala Phe Met  
85 90 95

Glu Met Asp Glu Ile Lys Pro Gly Pro Ile Val Ile Glu Leu Tyr Lys  
100 105 110

Lys Pro Thr Asp Phe Lys Arg Lys Lys Leu Gln Leu Leu Thr Lys Lys  
115 120 125

Pro Leu Tyr Leu His Leu His Gln Thr Leu His Lys Glu  
130 135 140

&lt;210&gt; 17

&lt;211&gt; 1737

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:cDNA derived  
from human mesenchymal stem cells after treatment  
with growth supplement

&lt;400&gt; 17

ggcacgagtc gacatggcgg ttaccctgag tctcttgctg ggccggcgcg tttgcgccgc 60  
cgtcactcgc tgtgggttcg cgaccgcggg ggtggcgggc ccaggcccta ttggccggga 120  
gccggaaccc gattccgact gggagccgga ggaacgggag ctgcaggagg ttgagaggta 180  
ccggcttctc cccgggcctc cagcttgaag cagggcctcg tgccccggcg ctcaggcccg 240  
cgcccccttg gcgcgggggt tctctgccgt gcttgccgag cggcccttgc ttctctttac 300  
ccgttgtagg gggcgccagc tcaggtgttc agctccccgg gaccacttgt ccttcattta 360  
gtgacgtatt tcactatcag tttagagagt tcggcatgct tacaggcagt tattgttcta 420  
gggtgttagt ttctgggtgt accgagcagc tctaagccgg caacatggcc cggttgcctt 480  
tgcatcaaaa gagaagaggg ctgggcgctc catgatttag cctgaggctc ttcaaacatc 540  
cattctgctt ccacgcatgg ctctcgccat tgggttctct cccccagcac cctgaaacga 600  
cagaacaacg caatccgatt ccagaaaatt cggaggcaaa tggaggcgcc tgggtccccc 660  
ccaggagccc tgacgtggga agccatggag cagatacgtt attacatga ggaatttcca 720  
gagtcctcgt cagttcccgag gtggctgtaa ggctttgatg tcagcactga gtgatccga 780  
agagttttta aaagcaagtt ttaccacca ttggagcaga agctgaagca ggatcaaaaa 840  
gtccttaaga aagctggggt tgcccactcg ctgcagcacc tccggggctc tggaaatacc 900  
tcaaaagctg tccctgcagg ccactctgta tcaggctctt tgcttatgcc agggcatgaa 960  
gcctcatcta aagaccacaa tcacagcaca gctttgaaag tgatagagtc agacactcac 1020  
aggacaataa caccgaaggag aaggaaggga agaataaaa aatccagga cctggaggag 1080  
agctttgtgc ctgttgctgc acccctaggt catccaagag agctgcagaa gtactccagt 1140  
gattctgaga gccccagagg aactggcagt ggtgcgtttg caagtgtgtca gaactggaga 1200  
gagttgaagg cagagggagcc agataaactc agcagcaaa tagtcagag ggcccgagag 1260  
ttctttgaca gcaacgggaa ctctctgtac agaatttgag tcggggcctg gcttatggag 1320  
atgcctcgtg aaacacagct gggaagtat taatgtatat ggaacagcct ggattctctg 1380  
atatggataa gccaccttgg aataggaaga ggtgttgagc ctggactgtg ggaggaaaga 1440  
gctgcgtgga tagattcaaa ctctctgtgg tagtgctccc agtctgacct ctgtagacct 1500  
tcagtaacta cttctcttgc tttaggtctc tgrtgttga aagccatccc gtgtgtcatg 1560  
tgttgttaca attttctgtg atacttgcaa tttatgttgg agaagaagtg aaagtttgc 1620  
cttctgacct catttccctc ttgatcagtg aacactaaca ttttggggac aacttagtca 1680  
attgggtttc cttacaacaa aataaagtaa aatgtagcaa aaaaaaaaa aaaaaaa 1737

<210> 18  
 <211> 219  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Putative  
 protein derived from ORF of cDNA of SEQ ID NO: 17.

<400> 18  
 Met Glu Ala Pro Gly Ala Pro Pro Arg Thr Leu Thr Trp Glu Ala Met  
 1 5 10 15  
 Glu Gln Ile Arg Tyr Leu His Glu Glu Phe Pro Glu Ser Trp Ser Val  
 20 25 30  
 Pro Arg Leu Ala Glu Gly Phe Asp Val Ser Thr Asp Val Ile Arg Arg  
 35 40 45  
 Val Leu Lys Ser Lys Phe Leu Pro Thr Leu Glu Gln Lys Leu Lys Gln  
 50 55 60  
 Asp Gln Lys Val Leu Lys Lys Ala Gly Leu Ala His Ser Leu Gln His  
 65 70 75 80  
 Leu Arg Gly Ser Gly Asn Thr Ser Lys Leu Leu Pro Ala Gly His Ser  
 85 90 95  
 Val Ser Gly Ser Leu Leu Met Pro Gly His Glu Ala Ser Ser Lys Asp  
 100 105 110  
 Pro Asn His Ser Thr Ala Leu Lys Val Ile Glu Ser Asp Thr His Arg  
 115 120 125  
 Thr Asn Thr Pro Arg Arg Arg Lys Gly Arg Asn Lys Glu Ile Gln Asp  
 130 135 140  
 Leu Glu Glu Ser Phe Val Pro Val Ala Ala Pro Leu Gly His Pro Arg  
 145 150 155 160  
 Glu Leu Gln Lys Tyr Ser Ser Asp Ser Glu Ser Pro Arg Gly Thr Gly  
 165 170 175  
 Ser Gly Ala Leu Pro Ser Gly Gln Lys Leu Glu Glu Leu Lys Ala Glu  
 180 185 190  
 Glu Pro Asp Asn Phe Ser Ser Lys Val Val Gln Arg Gly Arg Glu Phe  
 195 200 205  
 Phe Asp Ser Asn Gly Asn Phe Leu Tyr Arg Ile  
 210 215

<210> 19  
 <211> 369  
 <212> DNA  
 <213> Artificial Sequence  
 <220>

<223> Description of Artificial Sequence:cDNA derived  
from human mesenchymal stem cells after treatment  
with growth supplement

```
<400> 19
cattaggtgt  caccaaaagt  ttaacaattc  Cttgggaatt  tataacaaa  aaatatctag  60
actaaaaata  gaataataag  ccctctgga  accactgcac  acctttccct  ctgtctcag  120
attaaactgc  tgcataaaat  gaggttattt  agcctgtttt  taaggaagcg  tctatttga  180
catgcattcc  tttgtttgtt  aataacatgt  acttttgtaa  aaatatttcc  ataataagc  240
cctgttgtgt  ggttagctgg  gtgtggactt  tctctccctt  cttgggggccc  ctctactca  300
cagtcgaagt  gccctttaga  actaaagatc  tggtaggatt  gggctcttat  tcaatagccc  360
ctcgtgccg                                     369
```

<210> 20

<211> 48

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Putative  
protein derived from ORF of cDNA of SEQ ID NO: 19.

<400> 20

```
Glu Ser Ile Arg Cys His Gln Ser Val Asn Asn Ser Leu Gly Ile Tyr
  1             5             10             15
```

```
Lys Gln Lys Ile Ser Arg Leu Lys Ile Glu Tyr Lys Ala Pro Leu Glu
      20             25             30
```

```
Pro Leu His Thr Phe Pro Ser Val Leu Arg Leu Asn Cys Cys Ile Lys
      35             40             45
```

<210> 21

<211> 2133

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:cDNA derived  
from human mesenchymal stem cells after treatment  
with growth supplement

```
<400> 21
cgggcagaga  aatcatttaa  ttaaggatt  gcagettaag  acttggcata  cgggatacttg  60
gatgacactg  atttctcttg  tagctgggca  aatcagtttc  ctcacaaaaa  gtgaatatgg  120
taaaattaca  tgtttatata  atagattgt  gagactcaat  aatagtttga  gagctcagta  180
ttatcttttg  aggaagaca  taatttccaa  atttgattag  aatttgaaaa  taaatcacat  240
tttgatcatt  gctagatact  gtgtctaaat  gtggaaaaac  ctttgagaag  gatttttcta  300
tttttttttg  actatttcaa  gtcaatagag  aaaagaatcc  tgttgaaatc  agtgaagtgg  360
tgataagtag  tgggtggaag  attacagctc  agacttaatt  ggtatagatt  ggaatatatt  420
agatgggtga  atttattaca  aagcaaatat  taccccaaat  tgtctcttaa  gaaaatcttc  480
ccccaatctg  ttaattgaaa  aaaaattgtg  gtacaatcct  tataaaattt  accatttttag  540
ccattttaaa  gctcttaatg  cagttcagtg  gcattaagta  cattcatttt  gctttgtttc  600
tataactgac  atccatctcc  agaaaagctt  tcatottgaa  aatctgttac  cgtacttatt  660
taacaataag  tctttatata  cctctctctc  cagccctcgg  caaccaccat  cctactttct  720
atctctgaat  tegactcttc  tattaatagg  tacctcatat  aagtggaaaca  tagagttatt  780
```

```

gccccctttttt gtgactggct tatttcactt agcataaatgt gcccaagagt catatatgtt 840
agcatggcgtc aggatttttat ttcttttaaa ggctaaaataa tgttccattg tatgtatatata 900
ccatatttttg cttattttttt caccttccat ggacatttag gttgtttcta ccttgtagggt 960
actgtgaaatc atgcagcccat aaacattgggt gttcaaatat atgttccagg tttctgttttc 1020
aattctttttg catatatacc cagaagttaa attgtctggg cacatagtca ttttatttttt 1080
aattttttttg aggaactgtc atattgtttt ctatagtggc tgcaccacca aaattttgaa 1140
tggagagaatc gtcagcatcc tgtttaataa attattttaa aaatcagctc tgagcaaatg 1200
aatttagaatc ttggaatatt tgacccaaaaa tcagttttac acgtacatag tatgtttactg 1260
ataaaggaatc gactagagta gtacacctac agttcttctgt ggcagagacc aggaggggggt 1320
gtaaaggaatc ttcttggggt taaaaaagca ggcagcattg atgaatcatg aagtcccccc 1380
tacctcctttt aatgggttttg taacaaagag atgcattcag gtgaaagtgt caagtctttt 1440
tgtaactatac gaataactgt tctttttgta attgtagaat tctttaactt tttttaggct 1500
gaagtagagac acatgaatca tttgggtctga aacttttgag accctatttg gtttgcttac 1560
atatgtgaaa atagttatcc aaataattgc gattgctatc aaataatttc aataatatca 1620
ttactttttt ttggtctaga gtcttctcct ccttaacctc tttctttttg gcgagacagg 1680
gtctcactct gttaccagg ctggagtgtc atggagtgat cactgccctt ttgaacttct 1740
gggtccaagt gatcctctca cctcagcttc ctgagtaggt gggactacag atgtgtgcca 1800
ccaagcctgg ctaattaaaa acaaatgttt aagccaggca tgggtggcta cactgtaat 1860
ttcagcaccct tggggaggcg aggcaggcgg atcacttgag gtcaggagtt caagaccagc 1920
ctggccaagat tgggtggaacc ctgcctctac taaaaacaca cacacaattt agccgggcat 1980
gggtggctggt gtctgtaatc ccagctgtgg gaggttgagg caggagaatc actgaacct 2040
gggaggttggg ggtttcagtg agccaagatc atttcacctc actccagcct ggggtgacagc 2100
gtaagactct ctcaaaaaaa aaaaaaaaaa aaa 2133

```

&lt;210&gt; 22

&lt;211&gt; 56

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Putative  
protein derived from ORF of cDNA of SEQ ID NO: 21.

&lt;400&gt; 22

```

Met Phe His Cys Met Tyr Ile Pro Tyr Phe Ala Tyr Ser Phe Thr Phe
  1                      5                      10                      15

```

```

His Gly His Leu Gly Cys Phe Tyr Leu Val Gly Thr Val Asn His Ala
                20                      25                      30

```

```

Ala Ile Asn Ile Gly Val Gln Ile Tyr Val Pro Ala Ser Ala Phe Asn
  35                      40                      45

```

```

Ser Phe Ala Tyr Ile Pro Arg Ser
  50                      55

```

&lt;210&gt; 23

&lt;211&gt; 1200

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: cDNA derived  
from human mesenchymal stem cells after treatment  
with growth supplement

&lt;400&gt; 23

```

ggccagaggt agcagcagca tggccgcgat ctatgggggt gttagggggg gaggcacacg 60
attccaggtc ctttttagct cagaggatgg gaagatctcg gcagaagcag atggactgag 120

```

```

cacaaaccac  tggctgatcg  ggacagacaa  gtgtgtggag  aggatcaatg  agatggtgaa  180
caggggccaata  cggaaagcag  ggggtggatcc  tctggtaccg  ctgcgaagct  tgggctatc  240
tctgagcggt  ggggaccagg  aggacgcggg  gaggatcctg  atcggagagc  tgagggaccg  300
atttccctac  ctgagtgaaa  gctacttaat  caccacogat  gccgcggcgt  ccacgcacac  360
agctacacccg  gatggtggag  ttgtgctcat  atctggaaca  ggctccaact  gcaggctcat  420
caacctcgat  ggcctcgaga  gtggctgcgg  cggctggggc  catatgatgg  gtgatgaggg  480
ttcagccctac  tggatcgcac  accaagcagt  gaaaatatgt  tttgactcca  ttgacaacct  540
agaggcggt  cctcatgata  tcggctacgt  caaacaggcc  atgttccact  atttccaggt  600
gcagatcgg  ctagggatac  tcactcacct  gtatagggac  tttgataaat  gcaggtttgc  660
tgggttttgc  cggaaaattg  cagaaggtgc  tcagcagaca  gacccccctt  cccgctatat  720
cttcaggaag  gctggggaga  tgctgggcag  acacatcgta  gcagtgttgc  ccgagattga  780
cccggtcttg  ttccagggca  agattggact  ccccatcctg  tcggtgggct  ctgtatggag  840
gagctgggag  ctgctgaagg  aaggttttct  tttggcgctg  acccagggca  gagagatcca  900
ggctcagaac  ttcttctcca  gcttcaccct  gatgaagctg  aggcactcct  ccgctctggg  960
tggggccagc  ctaggggcca  ggcacatcgg  gcacctcctc  cccatggact  ataggcccaa  1020
tgccattgcc  ttctattcct  acaccttttc  ctagggggct  ggtcccggtc  ccacccccct  1080
caagctcagt  ggacactggg  tctgaaagga  aggagtcctt  tgcttctctt  cctcttttta  1140
caaaaacaaa  catagaagaa  aataaatgca  ctttatccaa  aaaaaaaaaa  aaaaaaaaaa  1200

```

<210> 24

<211> 344

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Putative  
protein derived from ORF of cDNA of SEQ ID NO: 23.

<400> 24

```

Met Ala Ala Ile Tyr Gly Gly Val Glu Gly Gly Thr Arg Ser Glu
 1             5             10             15
Val Leu Leu Val Ser Glu Asp Gly Lys Ile Leu Ala Glu Ala Asp Gly
                20             25             30
Leu Ser Thr Asn His Trp Leu Ile Gly Thr Asp Lys Cys Val Glu Arg
                35             40             45
Ile Asn Glu Met Val Asn Arg Ala Lys Arg Lys Ala Gly Val Asp Pro
 50             55             60
Leu Val Pro Leu Arg Ser Leu Gly Leu Ser Leu Ser Gly Gly Asp Gln
 65             70             75             80
Glu Asp Ala Gly Arg Ile Leu Ile Glu Glu Leu Arg Asp Arg Phe Pro
 85             90             95
Tyr Leu Ser Glu Ser Tyr Leu Ile Thr Thr Asp Ala Ala Gly Ser Ile
 100            105            110
Ala Thr Ala Thr Pro Asp Gly Gly Val Val Leu Ile Ser Gly Thr Gly
 115            120            125
Ser Asn Cys Arg Leu Ile Asn Pro Asp Gly Ser Glu Ser Gly Cys Gly
 130            135            140
Gly Trp Gly His Met Met Gly Asp Glu Gly Ser Ala Tyr Trp Ile Ala
 145            150            155            160
His Gln Ala Val Lys Ile Val Phe Asp Ser Ile Asp Asn Leu Glu Ala

```

165 170 175

Ala Pro His Asp Ile Gly Tyr Val Lys Gln Ala Met Phe His Tyr Phe  
180 185 190

Gln Val Pro Asp Arg Leu Gly Ile Leu Thr His Leu Tyr Arg Asp Phe  
195 200 205

Asp Lys Cys Arg Phe Ala Gly Phe Cys Arg Lys Ile Ala Glu Gly Ala  
210 215 220

Gln Gln Gly Asp Pro Leu Ser Arg Tyr Ile Phe Arg Lys Ala Gly Glu  
225 230 235 240

Met Leu Gly Arg His Ile Val Ala Val Leu Pro Glu Ile Asp Pro Val  
245 250 255

Leu Phe Gln Gly Lys Ile Gly Leu Pro Ile Leu Cys Val Gly Ser Val  
260 265 270

Trp Lys Ser Trp Glu Leu Leu Lys Glu Gly Phe Leu Leu Ala Leu Thr  
275 280 285

Gln Gly Arg Glu Ile Gln Ala Gln Asn Phe Phe Ser Ser Phe Thr Leu  
290 295 300

Met Lys Leu Arg His Ser Ser Ala Leu Gly Gly Ala Ser Leu Gly Ala  
305 310 315 320

Arg His Ile Gly His Leu Leu Pro Met Asp Tyr Ser Ala Asn Ala Ile  
325 330 335

Ala Phe Tyr Ser Tyr Thr Phe Ser  
340

&lt;210&gt; 25

&lt;211&gt; 2216

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:cDNA derived  
from human mesenchymal stem cells after treatment  
with growth supplement

&lt;400&gt; 25

ggcacgaggg gcaccgtaac cagcgccgcy gacaccggca cggcgccac ggactccgca 60  
ggaccccgcy ccgcgcgcgc ccgctatgct ggggctgcty gtggcgctgc tggccctggy 120  
gctcgctgtc ttgcgctgc tggacgtctg gtacctgggt cgcttccgt gcgcgctgct 180  
cgcgcgcgcy cctctgcagc cgcgctgcty tgacctgcta gctgagcagc gcttcccggy 240  
ccgcgctgct ccctcggaat tggacctgct gttgcacatg aacaacgcgc gctacctgcy 300  
cgagcccgac ttgcgcgcgc tcgcgcacct gaccgcgtgc ggggtgctcy gggcgctgag 360  
ggagttgcgg gcgcacacgg tgctggcgcy ctgctgcgcg cgccaccgcy gctcgctgcy 420  
cctgctggag cccttgagag tgcgcaccgc cctgctgggc tgggacgac gcgcgttcca 480  
cctggaggcy cgctttgtca gcttgcggga cggtttctgt tgccgctgcy tgcgcttcca 540  
gcagcaactg ctgggcacct caccgagcy cgtctgcag cacctgtgcy agcgagggt 600  
ggagccccc gagctgccc ctgatctgca gcactggatc tctacaacg aggcagcag 660  
ccagctgctc cgcatggaga gtgggctcag tgatgtcacc aaggaccagt gaccgcacc 720  
ttcacacgt ctgcctggc caccatccty ggcctggggg ctgcccacag atgggcagtc 780  
tcagccatcc tctgttccag ctggagtagc ctcccgacca gcttgcccca cctgctcca 840

```

ccccctgggc cccccagtt attgataccc ctctgtgctg ggctccacgc taggcagaag 900
gaggagtgcc attggcatcc tgaccagct ctgccctcaa ggtggggatg gatgggcaaa 960
ggagagtcct gccctggcct acgatgagge cactcatgtg ggcctaggta ggggaggatg 1020
gtgcctggag cagaggagacc cacaagtgc tcccgagcct agatcctggc tcggaccact 1080
gcaaggggcc aggcagggcc agaccagagc atcctgggta caggcctggg ctctccaggg 1140
cctggggcctg attcaggtgc agtggggcact cctgaagggt cagagcggca tctgccaggc 1200
agccccctctg gcttcccgctg aggtgggttgc aggcctgggg cagagcctgg gtggtcagag 1260
gcgggggctg gaggcagatg gaaggagggc atttgcgtac agaggacggg gcaccggggc 1320
tccccactgc agtcggcctt gccctcctct cctcctctac ctccagtcag gctggacggg 1380
agggtagcct tgtggctgag aggggtcaga ctagggtgga caggggctcc tggaaagaca 1440
gcaggcttcc tgtggggcgt tcccttgttg gagggaatag agtgggggtg ggaactctga 1500
gggtgtctct tgtccactcg caccctcgc cgccaccag ggcctatgct tgtgacttgg 1560
gctgatcccc accctttctg ggccctacag accacaggcc gctgtacccc cttagagctg 1620
ccccctctcg gcctggcggg caggcgtctt cttaactcct ctgtcctcta tattcagcat 1680
gttccttctg agctgctggg ccggccctgc cttgcgctag cagagcctct cctggcagct 1740
tctcaggtct ccctaattgga gacaccaggc tactaggaca ctggctgggg ccacccctc 1800
ctgcctaatg cctcacctta cagctgggga aactgaggcc tggaaatggc cagagtcacc 1860
aaggcaaaat tggggctggt cccagcctga ggctccagct gatgccctca gctcccagag 1920
aggggggtgcc ccatctagct ggggtgcagg gtcaactggt gtcagctcag ggccctgtgc 1980
ccgcttgccct gttccctcac atctgtgcct gcacatccag aactgcctcc ttgccgctgc 2040
ctccaggaaag cccacgttga gccagagtca agggctgcag cactgcccga tagaacacgc 2100
ccgcctctac tgctgtctt gccctacagc caccatggga aagctgcaac ctttctgttt 2160
tatttaaaga aagcccaaca ttaaagggtt ttcattgcga aaaaaaaaaa aaaaaa 2216

```

&lt;210&gt; 26

&lt;211&gt; 208

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Putative  
protein derived from ORF of cDNA of SEQ ID NO: 25.

&lt;400&gt; 26

```

Met Leu Gly Leu Val Ala Leu Leu Ala Leu Gly Leu Ala Val Phe
  1                      5                      10                      15

```

```

Ala Leu Leu Asp Val Trp Tyr Leu Val Arg Leu Pro Cys Ala Val Leu
                20                      25                      30

```

```

Arg Ala Arg Leu Leu Gln Pro Arg Val Arg Asp Leu Leu Ala Glu Gln
        35                      40                      45

```

```

Arg Phe Pro Gly Arg Val Leu Pro Ser Asp Leu Asp Leu Leu Leu His
        50                      55                      60

```

```

Met Asn Asn Ala Arg Tyr Leu Arg Glu Ala Asp Phe Ala Arg Val Ala
        65                      70                      75                      80

```

```

His Leu Thr Arg Cys Gly Val Leu Gly Ala Leu Arg Glu Leu Arg Ala
        85                      90                      95

```

```

His Thr Val Leu Ala Ala Ser Cys Ala Arg His Arg Arg Ser Leu Arg
        100                      105                      110

```

```

Leu Leu Glu Pro Phe Glu Val Arg Thr Arg Leu Leu Gly Trp Asp Asp
        115                      120                      125

```

```

Arg Ala Phe Tyr Leu Glu Ala Arg Phe Val Ser Leu Arg Asp Gly Phe
        130                      135                      140

```

Val Cys Ala Leu Leu Arg Phe Arg Gln His Leu Leu Gly Thr Ser Pro  
 145 150 155 160

Glu Arg Val Val Gln His Leu Cys Gln Arg Arg Val Glu Pro Pro Glu  
 165 170 175

Leu Pro Ala Asp Leu Gln His Trp Ile Ser Tyr Asn Glu Ala Ser Ser  
 180 185 190

Gln Leu Leu Arg Met Glu Ser Gly Leu Ser Asp Val Thr Lys Asp Gln  
 195 200 205

&lt;210&gt; 27

&lt;211&gt; 2453

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Consensus  
 sequence of the coding strand of cDNAs from human  
 mesenchymal stem cell genes.

&lt;400&gt; 27

gaattcgcca cgaggtcgcg gcggcggaagg agaggaggag agagggcgag gcgacaagag 60  
 aagaagggag caggcgcggg gcgacgagg gcgccccgag ccggcgagg cgaggggggg 120  
 gaagatggcg gacgtgttta gcgtctcgcg acagtacaac atccagaaga aggagattgt 180  
 ggtgaaggga gacgaagtga tcttcgggga ttctctctgg cccaagaatg tgaagccaa 240  
 ctatgtgttt tgggggactg gaaagggaagg ccaaccaga gactactaca cattggattc 300  
 cattttattt ctacttaata acgtgcacct ttctcatctt gttttatgtc gacgtgcagc 360  
 tactgaaaaa attcctgtgg ttagaagacc tgatcgaaaa gatctacttg gatattctaa 420  
 tggtagaagg tcaacatcgg caagtataga cagaagcgct cccttagaaa taggtcttca 480  
 gcgatctact caagtcaaac gagctgcaga tgaagtttta gcagaagcaa agaaaccacg 540  
 aattgaggat gaagagtggt tgcgccttga taaagagaga ttggctcgcc gtttggaggg 600  
 tcacaaagaa gggattgtac agactgaaca gattaggtct ttgctgaag ctatgtcagt 660  
 ggaataaatt gctgcaatca aagccaaaat tatggctaag aaaagactca ctatcaagac 720  
 tgatctagat gatcacataa ctgcctttaa acagaggagt ttgtggatg ctgaggtaga 780  
 tgtgaccgga gatattgtca gcagagagag agtatggagg acacgaacaa ctatcttaca 840  
 aagcacagga aagaattttt ccaagaacat ttttgcattt ctccaactctg taaaagccag 900  
 agaagaaggg cgtgcacctg aacacgcgacc tgccccaaat gcagcacctg tggatccac 960  
 ttgctgcacc aaacgcgcta tcccagctgc ctataacaga taccgatcagg aaagattcaa 1020  
 aggaataagaa gaaacgggaag gcttcaaaat tgacactatg ggaacctacc atggattcaa 1080  
 actgaaatct gtaacgggag gtgcattcgc ccggaagact cagactcctg cagccagacc 1140  
 agtacaaga cagttttctc aagcaagacc tccccaaat cagaagaagg gatctcgaac 1200  
 accattatac ataattctcg cagctaccac ctctttaata accattctta atgcaaaaga 1260  
 ccttctacag cagctgaaat ttgtcccatc agatgaaaag agaaaacaag gttgtcaacg 1320  
 agaaaatgaa actctaatca aaagaagaaa agaccagatg caaccagggg gcactccaat 1380  
 tagtgttaca gatccttata gactagttag ccagccctt aaacttatgc ctcaagactg 1440  
 ggaccgcgtt gtaccggttt ttgtgcaggg tctgtcatgg cagttcaaa gttggccatg 1500  
 gcttttgctt gatgatcac cagttgatat ttgtgtctaa attaaagcct tccattctgaa 1560  
 gtatgatgaa gttcgtctgg attccaaatg tcagaaatgg gatgtaacag tattagaact 1620  
 cagctatcac aaacgtcatt ttgatagacc agtgttctta cgggttttggg aaacatttga 1680  
 gatgtacatg gtaaacgata aatgcacatt gagattctga attattttgg tctccattgt 1740  
 ctggaaatct agactcaagc ttattgaatt tatcaagaac ttaaaaatga agaaggtcac 1800  
 atgtgatctt ttataaagag cttattttgt tcaagggatg gataactgtc 1860  
 atccataaa gcaaaccttt ttggttcaaa ctattttttt aatattagcc ttctagtctg 1920  
 taatggaat tgcatatttt gatagaagtt ttttctccat tgggttaaat agcattactt 1980

```

aaaatttggt  tctttagaaa  ataaatgcag  gttataaaatg  tgtgtatatt  tagagattat  2040
aaggctctct  gagccatctt  ctgatttttc  attgctctat  aattcttttt  actgaaaaata  2100
ctatgttatt  aatgttatta  aatttttagt  tctggaaacat  ccaaaaccaa  gcaaaagggat  2160
gtgactattt  tgaatgaatc  agaattgtcaa  ctgttatgta  cactatatct  acacttactc  2220
attattttaa  aagaataatg  aaaaatctag  atcaattctt  caatttgatt  gaactgttca  2280
gccttttcaa  gatttcttta  tttacaaatg  attacattta  aatgaatgta  gattctttct  2340
actgactttg  gtgattttga  aacctagaat  gatgtgtttc  tatctgtaat  atctttccat  2400
ttgaaaaaaa  tctcaaaaac  cagattaaaa  ccacaaaaaa  aaaaaaaaaa  aaa  2453

```

&lt;210&gt; 28

&lt;211&gt; 1593

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Coding sequence  
for the protein of SEQ ID NO:29 and corresponding  
to residues 125-1717 of SEQ ID NO:27

&lt;400&gt; 28

```

atggcggaag  tgccttagcgt  cctgcgacag  tacaacatcc  agaagaagga  gattgtgggtg  60
aaggggagacg  aagtgtatctt  cggggagttc  tccctggccca  agaattgtgaa  gaccaactat  120
gttggtttggg  ggaactggaaa  ggaaggccaa  cccagagaggt  actacacatt  ggaattccatt  180
ttatttctac  ttaataaacgt  gcacctttct  catcctgttt  atgtccgacg  tgcagctact  240
gaaaaatattc  ctgtggttag  aagacctgat  cgaaaagatc  tacttggata  tctcaatggt  300
gaagcgtcaa  catcggcgaag  tatagacaga  agcgctccct  tagaaataggt  tcttcacgca  360
tctactcaag  tcaaacgagc  tgcagatgaa  gttttagcag  aagcaaaaga  acccgaatt  420
gaggatgaag  agtgtgtgcg  ccttgataaa  gagagattgg  ctgcccgttt  ggaggggtcac  480
aaagaagggga  ttgtacacag  tgaacagatt  aggtctttgt  ctgaagctgt  gtcaagtggaa  540
aaaatttgtgt  caatacaaacg  caaaattatg  gctaagaaaa  gatctactat  caagactgat  600
ctagatgatg  acataaactgc  ccttaaacag  aggagttttg  tggatgctga  ggtagatgtg  660
acccgagata  ttgtcagcag  agagagagta  tggaggacac  gaacaactat  cttacaagaac  720
acaggaaaga  atttttccaa  gaacattttt  gcaattcttc  aatctgtaaa  agccagagaa  780
gaagggcggtg  cacctgaaca  gcgacctgcc  ccaaatgcag  cacctgtgga  tcccactttg  840
ggcaccacaa  agcctatccc  agctgcctat  aacagatagc  atcaggaaag  attcaaaaga  900
aaagaagaaa  cgggaaggctt  caaaattgac  actatggggaa  cctaccatgg  tatgacactg  960
aaatctgtaa  cggaggggtgc  atctgcccgg  aagactcaga  ctccctgcagc  ccagccagta  1020
ccaagaccag  ttctcacaag  aagacctccc  ccaaatcaga  agaaaggatc  tgaacacccc  1080
attatcataa  ttctctgcagc  taccactctc  ttaataacca  tgcttaattg  aaaagacctt  1140
ctacaggacc  tgaaaatttgt  cccatcagat  gaaaagaaga  aacaaaggtt  tcaacgagaa  1200
aatgaaactc  taatacaaac  aagaaaagac  cagatgcaac  cagggggcac  tgcattatgt  1260
gttacagtac  cttatagagt  agtagaccag  ccccttaaac  ttaagctctc  agactgggac  1320
cgcgttgtag  ccgtttttgt  gcagggtcct  gcaatggcag  tcaaaaggtg  gccatggctt  1380
ttgcctgatg  gatcaccagt  tgatatattt  gctaaaaatta  aagccttcca  tctgaagtat  1440
gatgaagatt  gctctgattc  aaatgttcag  aaatgggatg  taacagtatt  agaactcagc  1500
tatcacaac  gtcatttga  tagaccagtg  ttcttacggt  tttgggaaac  attggacagg  1560
tacatggtaa  agcataaact  gcacttgaga  ttc  1593

```

&lt;210&gt; 29

&lt;211&gt; 531

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Amino acid  
sequence derived from the nucleotide sequence of  
SEQ ID NO:28

&lt;400&gt; 29

Met Ala Asp Val Leu Ser Val Leu Arg Gln Tyr Asn Ile Gln Lys Lys  
 1 5 10 15

Glu Ile Val Val Lys Gly Asp Glu Val Ile Phe Gly Glu Phe Ser Trp  
 20 25 30

Pro Lys Asn Val Lys Thr Asn Tyr Val Val Trp Gly Thr Gly Lys Glu  
 35 40 45

Gly Gln Pro Arg Glu Tyr Tyr Thr Leu Asp Ser Ile Leu Phe Leu Leu  
 50 55 60

Asn Asn Val His Leu Ser His Pro Val Tyr Val Arg Arg Ala Ala Thr  
 65 70 75 80

Glu Asn Ile Pro Val Val Arg Arg Pro Asp Arg Lys Asp Leu Leu Gly  
 85 90 95

Tyr Leu Asn Gly Glu Ala Ser Thr Ser Ala Ser Ile Asp Arg Ser Ala  
 100 105 110

Pro Leu Glu Ile Gly Leu Gln Arg Ser Thr Gln Val Lys Arg Ala Ala  
 115 120 125

Asp Glu Val Leu Ala Glu Ala Lys Lys Pro Arg Ile Glu Asp Glu Glu  
 130 135 140

Cys Val Arg Leu Asp Lys Glu Arg Leu Ala Ala Arg Leu Glu Gly His  
 145 150 155 160

Lys Glu Gly Ile Val Gln Thr Glu Gln Ile Arg Ser Leu Ser Glu Ala  
 165 170 175

Met Ser Val Glu Lys Ile Ala Ala Ile Lys Ala Lys Ile Met Ala Lys  
 180 185 190

Lys Arg Ser Thr Ile Lys Thr Asp Leu Asp Asp Asp Ile Thr Ala Leu  
 195 200 205

Lys Gln Arg Ser Phe Val Asp Ala Glu Val Asp Val Thr Arg Asp Ile  
 210 215 220

Val Ser Arg Glu Arg Val Trp Arg Thr Arg Thr Thr Ile Leu Gln Ser  
 225 230 235 240

Thr Gly Lys Asn Phe Ser Lys Asn Ile Phe Ala Ile Leu Gln Ser Val  
 245 250 255

Lys Ala Arg Glu Glu Gly Arg Ala Pro Glu Gln Arg Pro Ala Pro Asn  
 260 265 270

Ala Ala Pro Val Asp Pro Thr Leu Arg Thr Lys Gln Pro Ile Pro Ala  
 275 280 285

Ala Tyr Asn Arg Tyr Asp Gln Glu Arg Phe Lys Gly Lys Glu Glu Thr  
 290 295 300

Glu Gly Phe Lys Ile Asp Thr Met Gly Thr Tyr His Gly Met Thr Leu  
 305 310 315 320

Lys Ser Val Thr Glu Gly Ala Ser Ala Arg Lys Thr Gln Thr Pro Ala

325										330					335				
Ala	Gln	Pro	Val	Pro	Arg	Pro	Val	Ser	Gln	Ala	Arg	Pro	Pro	Pro	Asn				
340									345			350							
Gln	Lys	Lys	Gly	Ser	Arg	Thr	Pro	Ile	Ile	Ile	Ile	Pro	Ala	Ala	Thr				
355									360			365							
Thr	Ser	Leu	Ile	Thr	Met	Leu	Asn	Ala	Lys	Asp	Leu	Leu	Gln	Asp	Leu				
370									375			380							
Lys	Phe	Val	Pro	Ser	Asp	Glu	Lys	Lys	Lys	Gln	Gly	Cys	Gln	Arg	Glu				
385									390			395			400				
Asn	Glu	Thr	Leu	Ile	Gln	Arg	Arg	Lys	Asp	Gln	Met	Gln	Pro	Gly	Gly				
405									410			415							
Thr	Ala	Ile	Ser	Val	Thr	Val	Pro	Tyr	Arg	Val	Val	Asp	Gln	Pro	Leu				
420									425			430							
Lys	Leu	Met	Pro	Gln	Asp	Trp	Asp	Arg	Val	Val	Ala	Val	Phe	Val	Gln				
435									440			445							
Gly	Pro	Ala	Trp	Gln	Phe	Lys	Gly	Trp	Pro	Trp	Leu	Leu	Pro	Asp	Gly				
450									455			460							
Ser	Pro	Val	Asp	Ile	Phe	Ala	Lys	Ile	Lys	Ala	Phe	His	Leu	Lys	Tyr				
465									470			475			480				
Asp	Glu	Val	Arg	Leu	Asp	Pro	Asn	Val	Gln	Lys	Trp	Asp	Val	Thr	Val				
485									490			495							
Leu	Glu	Leu	Ser	Tyr	His	Lys	Arg	His	Leu	Asp	Arg	Pro	Val	Phe	Leu				
500									505			510							
Arg	Phe	Trp	Glu	Thr	Leu	Asp	Arg	Tyr	Met	Val	Lys	His	Lys	Ser	His				
515									520			525							
Leu	Arg	Phe																	
530																			

What Is Claimed Is:

1. An isolated nucleic acid comprising a polynucleotide that is at least 90% identical to a polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting of  
5 SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 29.

2. An isolated nucleic acid comprising a polynucleotide that is at least 95% identical to a polynucleotide encoding a polypeptide  
10 comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 29.

3. An isolated nucleic acid comprising a polynucleotide that is at least 98% identical to a polynucleotide encoding a polypeptide  
15 comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 29.

4. An isolated nucleic acid comprising RNA corresponding to any of the DNA sequences or fragments of claims 1, 2 or 3.  
20

5. An isolated nucleic acid comprising a DNA sequence identical to a sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5,  
25 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 28 and the complements of these.

6. An isolated nucleic acid comprising RNA corresponding to the DNA sequence of Claim 5.  
30

7. An isolated nucleic acid comprising at least the polypeptide coding region of a human gene, said human gene containing a DNA sequence according to Claim 1.

5 8. An isolated nucleic acid comprising at least the polypeptide coding region of a human gene which contains the DNA sequence of Claim 5.

9. The isolated nucleic acid of claim 8 which expresses a  
10 human protein when in a suitable expression system.

10. A vector comprising the DNA sequence of claim 1.

11. A vector comprising the DNA sequence of claim 3.

15

12. A vector comprising the DNA sequence of claim 5.

13. A vector comprising the DNA sequence of claim 9.

20

14. A polypeptide coded for by the DNA sequence of claim 7 and active fragments, derivatives and functional analogs thereof.

15. A polypeptide coded for by the DNA sequence of claim 8 and active fragments, derivatives and functional analogs thereof.

25

16. A polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 29.

30 17. A genetically engineered cell having inserted into the genome thereof the DNA of Claim 7.

18. A process for producing cells for expressing a polypeptide using genetically engineered cells of claim 17.

19. An isolated DNA sequence comprising a fragment of a DNA of claim 5, wherein said fragment comprises at least 15 sequential bases of said sequence.

20. An isolated DNA sequence comprising a fragment of DNA of claim 5, wherein said fragment comprises at least 30 sequential bases of said sequence.

21. An isolated DNA sequence comprising a fragment of DNA of claim 5, wherein said fragment comprises at least 50 sequential bases of said sequence.

22. An isolated DNA sequence comprising a fragment of DNA of claim 5, wherein said fragment comprises at least 80 sequential bases of said sequence.

23. A method of detecting genes within the human genome comprising contacting a sample of said genome with an isolated DNA selected from the group consisting of the DNAs of claims 19, 20, 21, and 22.

24. A monoclonal antibody against a polypeptide selected from the group consisting of the polypeptides of claims 14 and 15.

## Figure 1

GAATTTCGGCA	CGAGGTCGCG	GCGGCGAAGG	AGGAGGAGGA	AGAGGGCGAG	GCACAAGAG	60
AAGAAGGAGG	CAGGCGCGCG	GGCAGCGCGG	GCGCCCGAG	CCGGCGGAGG	CGAGGGGGGG	120
AAGATGTCGG	GACGTGCTTA	GCSTCCTGCG	ACAGTACAAC	ATCCAGAAGA	AGGAGATTGT	180
GGTGAAGGGA	GACGAAGTGA	TCTTCGGGGA	GTTCCTCTGG	CCCAAGAATG	TGAAGACCAA	240
CTATGTTGTT	TGGGGGACTG	GAAAGGAAGG	CCAACCCAGA	GAGTACTACA	CATTGGATTG	300
CATTTTATTT	CTACTTAATA	ACGTGCACCT	TTCTCATCCT	GTTTATGTCC	GACGTGCAGC	360
TACTGAAAAT	ATTCTCTGGG	TTAGAAGACC	TGATCGAAAA	GATCTACTTG	GATATCTCAA	420
TGGTGAAGCG	TCAACATCGG	CAAGTATAGA	CAGAAGCGCT	CCCTTAGAAA	TAGGTCTCTA	480
CGGATCTACT	CAAGTCAAA	GAGCTGCAGA	TGAAGTTTTA	GCAGAAGCAA	AGAAACACAG	540
AATTGAGGAT	GAAAGTGTG	TGCGCCTTGA	TAAAGAGAGA	TTGGCTGCCC	GTTTGGAGGG	600
TCACAAAGAA	GGGATTGTAC	AGACTGAACA	GATTAGTCTT	TTGCTGAAG	CTATTCTCAAT	660
GGAAAAAATT	GCTGCAATCA	AAGCCAAAT	TATGGCTAAG	AAAAGATCTA	CTATCAAGAC	720
TGATCTAGAT	GATGACATA	CTGCCCTTAA	ACAGAGGAGT	TTTGTGGATG	CTGAGGTAGA	780
TGTGACCCGA	GATATTGTCA	GCAGAGAGAG	AGTATGGAGG	ACACGAACAA	CTATCTTACA	840
AAGCACAGGA	AAGAATTTTT	CCAAGAACAT	TTTTGCAATT	CTTCAATCTG	TAAAAGCCAG	900
AGAAGAAGGG	CGTGCACTTG	AACAGCGACC	TGCCCCAAAT	GCAGCACCTG	TGGATCCCA	960
TTTGCGCACC	AAACAGCCTA	TCCAGCTCTG	CTATAACAGA	TACGATCAGG	AAAGATTCAA	1020
AGGAAAAAGAA	GAAACGGAAG	GCTTCAAAAT	TGACACTATG	GGAACTTACC	ATGGTATGAC	1080
ACTGAAATCT	GTAACGGAGG	GTGCATCTGC	CCGGAAGACT	CAGACTCCTG	CAGCCACGCC	1140
AGTACCAAGA	CCAGTTTCTC	AAGCAAGACC	TCCCCAAAT	CAGAAGAAAG	GATCTCGAAT	1200
ACCCATTATC	ATAATTCCTG	CAGCTACCAC	CTCTTTAATA	ACCATGTCTA	ATGCAAAAGA	1260
CCTTCTACAG	GACCTGAAAT	TTGTCCCATC	AGATGAAAG	AAGAACAATG	GTTCCTCAAC	1320
AGAAAAATGAA	ACTCTAATAC	AAAGAAGAAA	AGACCAGATG	CAACCAGGGG	GCACTGCAAT	1380
TAGTGTTACA	GTACCTTATA	GAGTAGTAGA	CCAGCCCTTT	AAACTTATGC	CTCAAGACTG	1440
GGACCGCGTT	GTACCGCTTT	TTGTGCGAGG	TCTGCGATGG	CAGTTCAAAG	TTGGCCCATG	1500
GCTTTTGCT	GATGGATCAC	CAGTTGATAT	ATTGCTTAAA	ATTAAAGCCT	TCCATCTGAA	1560
GTATGATGAA	GTTCGTCTGG	ATCCAAATGT	TCAGAAATGG	GATGTAACAG	TATTAGAACT	1620
CAGCTATCAC	AAACGTCATT	TGGATAGACC	AGTGTCTCTA	CGGTTTTGGG	AAACATTGGA	1680
CAGGTACATG	GTAAGACATA	AATCGCACTT	GAGATTCTGA	ATTATTTGGC	TCCTCCATTT	1740
CTGGAAATTG	AGACTCAAGC	TTTATGAATT	TATCAAGAAC	TTAAAAATGA	AGAAGGTCAC	1800
AGATTGATCT	TTTATAAGAC	CTTATTTGAT	GCTTTGTGCT	TCAAGGAGAT	GATACCTGTC	1860
ATCCATATAA	GCAAACTTTT	TGGCTTACAA	CTATTTTTTT	AATATTAGCC	TTCTAGTCTG	1920
TAACTGAAAT	TGTATATTTT	GATAGAAGTT	TTTTCTCCAT	TGGTTAAAT	AGCATTACTT	1980
AAAATTTGTT	TCTTTAGAAA	ATAAATGCAG	GTTTATAAAT	TGTTATATAT	TAGAGATTAT	2040
AAGGCTCTCT	GAGGCTCTTT	CTGATTTTTT	ATTGCTCTAT	AATTCCTTTT	ACTGAAAAAT	2100
CTATGTTATG	AATGGTATTA	AATTTTATGC	TCTGGAAACAT	CCAAAACCAA	GCAAAAGGAT	2160
GTGACTATTT	TGAATGAATC	AGAATGTCAA	CTTGTATGTA	CACATATCTC	ACACTTACTC	2220
ATTATTTAAA	AAGATAAATG	AAAAATCTAG	ATCAATTTCT	CATTTTGATT	GAACCTGTTC	2280
GCCTTTTCAA	GATTTCTTTA	TTTACAATGT	ATTACATTTA	AATGAATGTA	CATTCTTCTC	2340
ACTGACTTTG	GTGATTTTGA	AACCTAGAA	GATGTGTTTC	TATCTGTAA	ATCTTTCCAT	2400
TTGAAAAAAA	TCTCAAAACA	CAGATTAAAA	CCACAAAAA	AAAAAAAAA	AAA	2453

**Figure 2**

MADVLSVLRQYNIQKKEIVVKGDEVIFGEFSWPKNVKTNVYVWGTGKEGQPREYITLDSI  
LFLNNVHLSHPVYV\*RR AATENI PVVRRPDRKD\*LLGYLNGEASTSASIDRSAPLEIGL  
QRSTQVKRAADEVLAEAKKPRIEDEECVRLDKERLAARLEGHKEGIVQTEQIRSLSEAMS  
VEKIAAIKAKIMAKKRSTIKTDLDDDTALEQRSFVDAEVDVTRDIVSRERVWRTRTTIL  
QSTGKNFSKNIFAILQSVKAREEGRAPEQRPAPNAAPVDPTLR TKQPIPAAYNRYDQERF  
KGKEETEGFKIDTMGTYHG MTLKSVTEGASARKTQTPAAQPVP RPVSQARPPPNQKKGSR  
TPIIIP AATTSLITMLNAKDLLQDLKFVPSDEK\*KKQGCQRENETLIQRRKD\*QMOPGG  
TAISVTVPYRVVDQPLKLPQDWD RVVAVFVQGP AWQFKGWPWLLPDGSPVDIFAKIKAF  
HLKYDEVRLDPNVQKWDVTVLELSYHKRHLDRPVFLRFWETLDRYMVKHKSHLRF

## Figure 3

Human RNA Master Blot.

	1	2	3	4	5	6	7	8
A	whole brain	amygdala	caudate nucleus	cerebellum	cerebral cortex	frontal lobe	hippocampus	medulla oblongata
B	occipital pole	putamen	substantia nigra	temporal lobe	thalamus	subthalamic nucleus	spinal cord	
C	heart	aorta	skeletal muscle	colon	bladder	uterus	prostate	stomach
D	testis	ovary	pancreas	pituitary gland	adrenal gland	thyroid gland	salivary gland	mammary gland
E	kidney	liver	small intestine	spleen	thymus	peripheral leukocyte	lymph node	bone marrow
F	appendix	lung	trachea	placenta				
G	fetal brain	fetal heart	fetal kidney	fetal liver	fetal spleen	fetal thymus	fetal lung	
H	yeast total RNA	yeast tRNA	E. coli rRNA	E. coli DNA	Poly r(A)	human Cöt DNA	human DNA	human DNA




Figure 4(A)

## DSC64: Tissue Distribution





Figure 4(B)



<b>COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY</b> (Includes Reference to PCT International Applications)		<b>ATTORNEY'S DOCKET NUMBER</b> 640100-430 Customer No.: 27162													
<p>As a below named inventor, I hereby declare that:</p> <p>My residence, post office address and citizenship are as stated below next to my name.</p> <p>I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:</p> <p style="text-align: center;">Human Mesenchymal DNAs and Expression Products</p> <p>the specification of which (check only one item below):</p> <p><input type="checkbox"/> is attached hereto.</p> <p><input checked="" type="checkbox"/> was filed as United States application          Serial No.           09/937,974          on                    October 1, 2001          and was amended on                   (if applicable)</p> <p><input checked="" type="checkbox"/> was filed as PCT international application          Number             PCT/US00/08751          on                    31 March 2000          and was amended under PCT Article 19          on                    (if applicable).</p> <p>I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.</p> <p>I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations §1.56(a).</p> <p>I hereby claim foreign priority benefits under Title 35 United States Code §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:</p>															
<b>PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:</b>															
COUNTRY (if PCT indicate PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center;">PRIORITY CLAIMED UNDER 35 USC 119</th> </tr> <tr> <td style="width: 50%; text-align: center;"> <input type="checkbox"/> YES         </td> <td style="width: 50%; text-align: center;"> <input type="checkbox"/> NO         </td> </tr> <tr> <td style="text-align: center;"> <input type="checkbox"/> YES         </td> <td style="text-align: center;"> <input type="checkbox"/> NO         </td> </tr> <tr> <td style="text-align: center;"> <input type="checkbox"/> YES         </td> <td style="text-align: center;"> <input type="checkbox"/> NO         </td> </tr> <tr> <td style="text-align: center;"> <input type="checkbox"/> YES         </td> <td style="text-align: center;"> <input type="checkbox"/> NO         </td> </tr> <tr> <td style="text-align: center;"> <input type="checkbox"/> YES         </td> <td style="text-align: center;"> <input type="checkbox"/> NO         </td> </tr> </table>	PRIORITY CLAIMED UNDER 35 USC 119		<input type="checkbox"/> YES	<input type="checkbox"/> NO	<input type="checkbox"/> YES	<input type="checkbox"/> NO	<input type="checkbox"/> YES	<input type="checkbox"/> NO	<input type="checkbox"/> YES	<input type="checkbox"/> NO	<input type="checkbox"/> YES	<input type="checkbox"/> NO
PRIORITY CLAIMED UNDER 35 USC 119															
<input type="checkbox"/> YES	<input type="checkbox"/> NO														
<input type="checkbox"/> YES	<input type="checkbox"/> NO														
<input type="checkbox"/> YES	<input type="checkbox"/> NO														
<input type="checkbox"/> YES	<input type="checkbox"/> NO														
<input type="checkbox"/> YES	<input type="checkbox"/> NO														

<b>COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY</b> (Includes Reference to PCT International Applications)				ATTORNEY'S DOCKET NUMBER 640100-430 Customer No.: 27162	
<p>I hereby claim the benefit under Title 35, United States Code, §120 or § 119 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:</p>					
<b>PRIOR U.S. APPLICATION(S) OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120 or U.S.C. 119:</b>					
<b>U.S. APPLICATIONS</b>			<b>STATUS (Check one)</b>		
U.S. APPLICATION NO.	U.S. FILING DATE	PATENTED	PENDING	ABANDONED	
60/127,418	1 April 1999		<input type="checkbox"/>	<input type="checkbox"/>	
60/148,800	13 August 1999				
<b>PCT APPLICATIONS DESIGNATING THE U.S.</b>					
PCT APPLICATION NO.	PCT FILING DATE	U.S. SERIAL NUMBERS ASSIGNED (if any)	<input type="checkbox"/>	<input type="checkbox"/>	
PCT/US00/08751	31 March 2000		<input checked="" type="checkbox"/>	<input type="checkbox"/>	
<p><b>POWER OF ATTORNEY:</b> As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (List name and registration number) John N. Bain (Reg. No. 18,651); John G. Gillilan III (Reg. No. 22,746); Elliot M. Olstein (Reg. No. 24,025); Raymond J. Lillie (Reg. No. 31,778); William Squire (Reg. No. 25,378); Alan Grant (Reg. No. 33,389); Francis C. Hand (Reg. No. 22,280) and Glenn Troubleshoot (Reg. No. 39,050)</p>					
Send Correspondence to: <u>Alan J. Grant, Esq.</u> <u>Carella, Byrne, Bain, Gillilan, Cecchi, Stewart &amp; Olstein</u> <u>6 Becker Farm Road, Roseland, New Jersey 07068</u>			Direct Telephone Calls to: (name and telephone number) (973) 994-1700		
201	FULL NAME OF INVENTOR <u>1-00</u>	FAMILY NAME <u>Van den Bos</u>	FIRST GIVEN NAME <u>Christian</u>	SECOND GIVEN NAME	
	RESIDENCE & CITIZENSHIP	CITY <u>Baltimore</u>	STATE OR FOREIGN COUNTRY <u>Maryland</u>	COUNTRY OF CITIZENSHIP <u>Germany</u>	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>2214 East Fairmont Avenue</u>	CITY <u>Baltimore</u>	STATE & ZIP CODE/COUNTRY <u>Maryland 21231</u>	
202	FULL NAME OF INVENTOR	FAMILY NAME <u>Mbalaviele</u>	FIRST GIVEN NAME <u>Gabriel</u>	SECOND GIVEN NAME	
	RESIDENCE & CITIZENSHIP	CITY <u>O'Fallon</u>	STATE OR FOREIGN COUNTRY <u>Missouri</u>	COUNTRY OF CITIZENSHIP <u>Republic of Congo</u>	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>8 Chastain Court</u>	CITY <u>O'Fallon</u>	STATE & ZIP CODE/COUNTRY <u>Missouri, 63366</u>	
203	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY	
<p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application of any patent issuing thereon.</p>					
SIGNATURE OF INVENTOR 201 <u>[Signature]</u>		SIGNATURE OF INVENTOR 202 <u>[Signature]</u>		SIGNATURE OF INVENTOR 203	
DATE <u>11/27/01</u>		DATE <u>12-04-01</u>		DATE	